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Abstract 
Application of Platelet-Rich Plasma in Combination with Cell-Based Therapy for Cartilage 
Repair 
 
Jr-Jiun Liou, PhD 
 
University of Pittsburgh, 2019 
 
 
 
 
Post-traumatic and focal cartilage defects of the knee affect over three million Americans 
annually. Autologous cell-based therapy, e.g., autologous chondrocyte implantation, is limited by 
the need for ex vivo chondrocyte expansion and donor site morbidity. Mesenchymal stem cells 
(MSCs), owing to their relative ease of isolation, higher replication activity, and chondrogenic 
potential, represent an alternative reparative cell type. Platelet-rich plasma (PRP) is an autologous, 
growth factor-rich biologic that has recently received increasing attention and use as a therapeutic 
adjunct for the treatment of degenerative joint diseases, and there is evidence suggesting that PRP 
acts by promoting stem cell proliferation and tissue healing. In this research, we have examined 
the effects of PRP treatment on chondrogenic differentiation of adult human MSCs derived from 
the infrapatellar fat pad (IFP-ASCs), maintained in high-density pellet cultures and hydrogel-
encapsulated cultures. Cells derived from the infrapatellar fat pad were shown to possess a greater 
chondrogenic potential than those derived from subcutaneous tissue, and ideally provide a 
convenient cell source for tissue regenerative procedures. Our results showed that IFP-ASC 
chondrogenesis is inhibited with increasing PRP concentrations and duration of exposure, based 
on histological, biochemical, and gene expression analyses. We identified vascular endothelial 
growth factor (VEGF) as a component of PRP that acts to impair the pro-chondrogenic activity of 
PRP on IFP-ASCs. We further tested the combination of ASCs with VEGF-depleted PRP 
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encapsulated with hydrogels for in vivo osteochondral defect repair in a rabbit model. Findings 
from this research provide information on the potential application of PRP in combination with 
cell-based therapy for cartilage repair. Our goal is to develop an optimal cell and biologic 
formulation for a potential point-of-care treatment of post-traumatic and focal cartilage defects, 
for the restoration of joint function and improvement of the quality of life. 
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1.0 Introduction 
Cartilage injuries affect more than 10 million people in the United States every year 
(National Research Council and the Institute of Medicine, 2001). These injuries remain a 
significant clinical problem not only due to the intense pain and potential for mobility loss but also 
because they represent the primary reason for visits to the doctor’s office and contribute to the 
majority of physical disabilities (National Research Council and the Institute of Medicine, 2001). 
The burden of musculoskeletal diseases is well recognized, afflicting more than 20% of the 
population, higher than cancer and cardiovascular disease combined (National Research Council 
and the Institute of Medicine, 2001). Understanding the nature and cause of musculoskeletal soft 
tissue injuries is thus highly relevant.  This chapter reviews the nature and current treatments for 
cartilage injuries, and the knowledge gaps in effective therapies.  The potential of tissue 
engineering and regenerative medicine approaches is highlighted with examples, featuring both 
promises and challenges for future investigations.1 
 
                                                 
1The Introduction contains materials from the publication - Liou, J. J., Langhans, M. T., Gottardi, R., & Tuan, 
R. S. (2016) Injury and Repair of Tendon, Ligament and Meniscus, Advances in Translational Medicine Regenerative 
Medicine, Chapter 6. 
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1.1 Cartilage 
1.1.1  Structure and Function 
Articular cartilage (AC) of the knee covers the femoral and tibial surface and can also be 
found on the back of patella. AC primary functions include transmission of applied loads across 
the mobile surface, alignment of the ends of bones as well as permitting rolling or sliding during 
movement (Masouros, Bull, & Amis, 2010). Cartilage is composed of 1% chondrocytes, 29% 
extracellular matrix, and 70% water. Among all extracellular matrix proteins, collagen type II is 
the most abundant component that provides tensile strength to the cartilage tissue. Proteoglycan, 
another key molecule of AC, is composed of proteins and sugars that contain negative charges. 
The repulsive force between negative charges provides increased compressive strength for the 
cartilage tissue (Han, Chen, Klisch, & Sah, 2011). Link protein, hyaluronan, core aggrecan protein, 
and glycosaminoglycan are four components of proteoglycans. The complexity of the organization 
between the cells and extracellular matrix constituents is critical for the unique biomechanics of 
cartilage.  
Because of the limited availability of differentiated cartilage cells, i.e., chondrocytes, 
cartilage tissue engineering using adult tissue-derived, multipotent mesenchymal stem cells 
(MSCs) has been actively pursued for the past two decades. Adult MSCs can undergo condensation 
and chondrogenic differentiation and become mature chondrocytes with appropriate induction. 
Challenges on how to induce chondrogenic differentiation at the chosen time and the desired 
location remain. A variety of natural materials, including silk, fibrin, hyaluronic acid, collagen, 
gelatin, chitin, chitosan, tricalcium phosphate, and hydroxyapatite, have been utilized as 
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biomaterial scaffolds for neo-cartilage tissue formation; however, there is no agreed perfect 
material as of yet (J. Yang, Zhang, Yue, & Khademhosseini, 2017; P. J. Yang & Temenoff, 2009). 
Collagen scaffolds, in particular, have been utilized in a currently practiced surgical 
technique - matrix-assisted autologous chondrocyte implantation (MACI) – for repair of focal 
cartilage defects (Brittberg et al., 1994; Brittberg, Nilsson, Lindahl, Ohlsson, & Peterson, 1996; 
Freymann, Petersen, & Kaps, 2013; E Kon, Filardo, Di Matteo, Perdisa, & Marcacci, 2013; 
Makris, Gomoll, Malizos, Hu, & Athanasiou, 2015). In the first generation of MACI, a collagen 
membrane was used to cover chondrocyte implantation site. The second generation of MACI 
utilizes collagen hydrogel scaffold to encapsulate chondrocytes to support cell growth. Challenges 
of MACI include donor site morbidity, low availability of chondrocytes, and loss of chondrocyte 
phenotype during cell expansion. 
To engineer a fully functional cartilage tissue, a principal concern is an adequate 
mechanical strength since the major function of articular cartilage is to support the applied loads 
for the entire body. Weight-bearing regions must withstand repetitive mechanical loading to ensure 
joint function after an operation. The neo-cartilage must possess both biological characteristics 
and mechanical properties of native cartilage; The compressive modulus of native cartilage is 1 
MPa (Moutos et al., 2016). Currently, numerous investigators are exploring different combinations 
of natural or synthetic materials to optimize the mechanical properties of neo-cartilage tissues. 
Using condensed mesenchymal cell bodies, Young’s modulus can reach up to 700 kPa 
(Bhumiratana et al., 2014), alginate reinforced with polycaprolactone scaffolds can reach as high 
as 6000 kPa (Schuurman et al., 2011), polyethylene glycol at 4000 KPa (Woodfield et al., 2004, 
2005) with polycaprolactone-hydroxyapatite scaffolds an excess of 5000 kPa (C. H. Lee et al., 
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2010). A review of current cartilage tissue engineering systems with relevant information of 
materials and mechanical properties is presented by (Mouser et al., 2017).  
In the cartilage growth plate of the developing endochondral skeleton, mesenchymal cells 
condense and then differentiate into chondrocytes, form flat columnar chondrocytes, become pre-
hypertrophic chondrocytes and hypertrophic chondrocytes, ultimately mature to terminal 
hypertrophic chondrocytes. Terminal hypertrophic chondrocytes are withdrawn from the cell cycle 
and commit to apoptosis (Ruijtenberg & van den Heuvel, 2016; Zuscik, Hilton, Zhang, Chen, & 
O’Keefe, 2008), exhibiting an inverse relationship between proliferation and differentiation 
(Ruijtenberg & van den Heuvel, 2016). 
1.1.2  Injury and Intrinsic Healing 
Cartilage injuries occur during traumatic injuries or repeated unbalanced stress. The major 
symptom is pain and loss of joint function. Cartilage lesions can be categorized into four different 
severity levels: Grade I to Grade IV. Grade I represents the cartilage with soft spots or superficial 
wears; Grade II represents minor tears with lesions less than half thickness of cartilage; Grade III 
usually represents lesions that are deeper than half thickness of cartilage; patients diagnosed as 
Grade IV usually have full-thickness cartilage defects with subchondral bone exposed. 
Due to lack of vasculature in cartilage, intrinsic healing is poor, and to repair damaged 
cartilage, surgical procedures are usually required. Unlike muscle strain and bone fracture, 
physical therapy is of little help. 
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1.1.3  Current Treatment Approaches 
Current surgical techniques for treating focal cartilage defects include osteochondral 
autograft/allograft transplantation, microfracture, and autologous chondrocyte implantation 
(Figure 1A). In osteochondral autograft/allograft transplantation, the surgery involves harvesting 
osteochondral plugs from the donor site and osteochondral plug transplantation to the defect site 
(Figure 1B). Another surgical procedure – microfracture – involves drilling into subchondral bone 
to induce bleeding and release bone marrow, which contains clotting factors and mesenchymal 
stem cells. 
In autologous chondrocyte implantation (ACI), autologous chondrocytes are isolated from 
non-weight bearing cartilage, expanded ex vivo, and returned to the chondral defect as a cell 
suspension covered with a collagen membrane (Huang, Hu, & Athanasiou, 2016). More recently, 
matrix-assisted ACI (MACI) has been developed (Figure 1C). In MACI, autologous chondrocytes 
are seeded within a three-dimensional scaffold before implantation, for better integration with the 
surrounding native cartilage while also providing a biomimetic microenvironment capable of 
enhancing cartilage neotissue formation (Freymann et al., 2013; E Kon et al., 2013; Makris et al., 
2015).  Although both ACI and MACI have shown promise, challenges persist. Chondrocyte yield 
from non-weight bearing cartilage is low, requiring ex vivo cell expansion with an accompanying 
loss of the chondrogenic phenotype (Tuan, Chen, & Klatt, 2013). As a result, the patient must 
undergo two surgical procedures, and the quality of cartilage repair remains inconsistent. 
Identification of alternative cell sources and the application of chondroinductive scaffolds are 
needed to overcome these challenges, permitting a single-step procedure with robust cartilage 
formation. 
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Figure 1. Current surgical techniques for treating focal cartilage defects. 
Cartilage defects usually require a surgical procedure to repair. Photo adapted from the internet2. (B) 
Osteochondral allograft transplantation is a technique that allograft is cored and trimmed to the appropriate 
dimensions and filled the defect. Photo credit: Jr-Jiun Liou. (C) Matrix-assisted autologous chondrocyte 
implantation is a two-step procedure: first procedure autologous articular cartilage is harvested, and the autologous 
chondrocytes are isolated and expanded ex vivo; during second procedure, autologous chondrocyte mixed in 
collagen solution is injected to the chondral defect with collagen membrane as a cover and fibrin gel as glue. Photo 
credit: Jr-Jiun Liou. 
1.2 Cartilage Tissue Engineering 
The field of tissue engineering was introduced more than two-and-a-half decades ago to 
describe the combination of biological principles and engineering technologies for developing 
functional replacement of degenerated, injured, or diseased tissues and organs. Regenerative 
medicine refers to clinical applications of these therapeutic procedures. Successful tissue 
engineering and regenerative medicine approaches require cells, scaffolds or matrices, and 
                                                 
2 http://www.porcpotlas.hu/en/mozaikplasztika.html 
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bioactive factors, that when combined can facilitate the productive, conductive, and inductive 
activities, respectively, of tissue regeneration. 
1.2.1  Cells 
Chondrocytes are mature cells present in cartilage tissues. Many studies have intensively 
investigated the potential of chondrocyte-derived tissues. However, chondrocytes undergo 
dedifferentiation during cell expansion and typically lose their cartilage phenotype, resulting in 
fibroblastic cells. Unlike fibroblasts or MSCs, doubling time of chondrocytes may be as long a 3.5 
days; which presents challenges to reach sufficient cell populations for one-step procedures (Akens 
& Hurtig, 2005). Strategies for maintaining chondrocyte phenotype have been reported. When 
mixed with bone marrow-derived MSCs (BM-MSCs) in alginate hydrogels before subcutaneous 
implantation, chondrocytes were able to maintain their phenotype for up to 6 weeks; however, the 
mechanical strength of alginate hydrogel used in this study may not be sufficient when implanted 
into articular joint (Fedorovich et al., 2012). Another research group reported chondrocytes 
cultured on beta-glycerophosphate containing calcium polyphosphate for development of 
cartilage-bone interface (Allan, Pilliar, Wang, Grynpas, & Kandel, 2007). This study indicated that 
calcium phosphate and beta-glycerophosphate are both necessary for calcified cartilage 
development (Allan et al., 2007).  
To understand the regulation of differentiation and de-differentiation of articular 
chondrocytes, researchers have also focused on studying how chondrocytes are formed during 
embryonic development. In early embryonic development, the endochondral ossification process 
of skeletogenesis is initiated by mesenchymal condensation, followed by chondrogenic 
differentiation to form a cartilage template (Carlevaro, Cermelli, Cancedda, & Descalzi Cancedda, 
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2000; Kronenberg, 2003). Growth and maturation of the cartilage template in the growth plate 
result in chondrocyte hypertrophy, accompanied by the upregulation of vascular endothelial 
growth factor (VEGF) and subsequent vascularization (Carlevaro et al., 2000; Karimian, Chagin, 
& Sävendahl, 2011). During this event, the hypertrophic chondrocytes undergo apoptosis and are 
replaced by osteoblasts, ultimately resulting in bone formation (Carlevaro et al., 2000; Karimian 
et al., 2011). While the critical steps that lead to hypertrophy are still incompletely understood, 
VEGF is believed to play an important role. 
Due to the limitations in culturing chondrocytes, stem cells have become an alternative cell 
source. Stem cells can be divided into two different categories: pluripotent stem cells (e.g., 
embryonic stem cells, ESCs, and induced pluripotent stem cells, iPSCs) and multipotent stem cells. 
iPSCs were first produced from mouse fibroblasts via viral transduction of four transcription 
factors – Oct4, Sox2, cMyc, and Klf4 in 2006 (Kazutoshi Takahashi & Yamanaka, 2006). Like 
ESCS, iPSCs were shown to possess unlimited self-renewal and proliferation potential (K. 
Takahashi et al., 2007; Wernig et al., 2007; Yamanaka, 2007; J. Yu et al., 2007). Compared to 
adult MSCs, iPSCs have longer telomere length and can potentially become a practically unlimited 
cell source without compromising the differentiation capacity (Marión & Blasco, 2010). During 
embryonic development, embryonic stem cells develop into three different germ layers: the 
endoderm, mesoderm, and ectoderm (Langhans, Yu, & Tuan, 2015). As the applicability of iPSCs 
for tissue engineering is still an area of active research and has not been established, it is not within 
the scope of this dissertation. 
The other category is adult mesenchymal stem cells (MSCs). MSCs have the ability of self-
renewal and multi-potency. For example, they can undergo condensation and chondrogenic 
differentiation and become mature chondrocytes with appropriate induction. MSCs have 
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traditionally been isolated from the bone marrow, an invasive and often painful procedure that 
yields a relatively low percentage of MSCs. Alternatively, adipose tissue contains a higher 
percentage of MSCs, is abundantly available, and can be harvested through a minimally invasive 
lipoaspiration procedure (Hildner et al., 2015). Recently, human MSCs derived from the 
infrapatellar fat pad (IFP-ASCs) were shown to possess a greater chondrogenic potential than 
subcutaneous ASCs (SQ-ASCs) (Lopa et al., 2014) and may ideally provide a stem cell source in 
one-step procedures.  
Infrapatellar fat pad (IFP), or Hoffa’s fat pad, is located underneath the patellar tendon. 
Hoffa’s disease is caused by acute injuries or chronic unbalanced stresses, and the major symptom 
is pain due to impingement from femur or tibia to the fat tissue. The fat tissue is approximately 
21-39 mL in size, dependent on the individual (Jason L. Dragoo, Johnson, & McConnell, 2012). 
IFP, like other fat tissues, is highly vascularized and innervated. Cells resident within the IFP 
include adipocytes, fibroblasts, and multipotent MSCs (IFP-ASCs), which have been harvested 
and utilized in tissue engineering approaches. The exact function of IFP is still unclear, but it has 
been hypothesized that IFP serves as cushioning and a reservoir of reparative cells (Jason L. 
Dragoo et al., 2012). Surgically, the IFP can be harvested by a small incision arthroscopically (Koh 
& Choi, 2012). This procedure is less invasive when compared to bone marrow harvest. The total 
cell numbers harvested from 21 mL of IFP average 5.5 x 106 cells, while the average from 30 mL 
of bone marrow aspirate is 1.0 x 105 cells (Bruder, Jaiswal, & Haynesworth, 1997; J L Dragoo et 
al., 2003). Due to their less invasive derivation and autologous nature, IFP-ASCs were chosen to 
be the main cell type used in this dissertation research. 
However, the volume of IFP is still relatively small when compared to subcutaneous 
tissues, which usually range 200 mL, so the total cell number of IFP is limited (G. Yu et al., 2010). 
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Therefore, ex vivo culture expansion of IFP-ASCs would likely be required to obtain a sufficient 
cell number for implantation. Alternatively, it may be possible to promote IFP-ASC proliferation 
at the site of implantation, thereby allowing the intraoperative isolation of IFP-ASCs and 
implantation into a chondral defect. 
Adult multipotent stem/progenitor cells, by virtue of their extensive proliferative activity 
and multi-lineage differentiation potential, are thus considered prime candidate cells for tissue 
engineering and regenerative medicine.  For musculoskeletal applications, adult stem cells, such 
as MSCs, most commonly derived from bone marrow and adipose tissue, are of interest due to the 
relative ease of their isolation and enrichment, safety, and freedom from ethical issues. MSCs 
cultured in the presence of specific growth factors and inductive supplements may be induced to 
differentiate into specific musculoskeletal tissue lineages, including chondrocytes and osteoblasts.  
For the induction and enhancement of MSC chondrogenesis, several growth factors have been 
shown to be highly active, in particular transforming growth factor (TGFβ).  Of interest is the 
recent attention on platelet enriched products, including plasma platelet-rich plasma (PRP) and 
platelet-rich fibrin (PRF), as bioactive additives to enhance the repair of cartilage. 
ASCs have been widely studied because of the abundance of fat disposed after surgery. 
MSCs may be derived from either autologous or allogeneic sources. Open surgery, ex vivo cell 
expansion and iatrogenic damage caused by autologous stem cell harvesting are not preferable. 
The other disadvantage of using autologous stem cells, particularly from elderly individuals, 
relates to the age-associated reduction in proliferative and differentiation activities of MSCs. 
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1.2.2  Biomimetic Scaffolds 
In addition to cells, a biocompatible scaffold is beneficial in promoting cell growth and 
differentiation, as well as acting as a 3-dimensional volumetric adduct. As mentioned, the MACI 
technique utilizes collagen hydrogel as seeding scaffold. Materials including synthetic materials 
that degrade over time and native biomaterials derived from tissues have been investigated. 
Poly(lactic-co-glycolic acid) (PLGA), poly(L-lactic acid) (PLLA) and poly(-caprolactone) (PCL) 
are the most common synthetic biodegradable polymers in use. Kuo et al. summarized current 
synthetic polymeric scaffolds and native biomaterials in tendon and ligament tissue engineering 
(Kuo, Marturano, & Tuan, 2010). PLLA showed better performance compared to PLGA scaffold 
regarding degradation profiles (Kuo et al., 2010). A recent study adopted a rational design of 
nanofiber scaffolds for tendon regeneration using PLGA and PCL seeded with stem cells and 
implanted into different animal models, and reported favorable outcomes; however, the prevention 
of adhesion after the repair was not investigated (Ma, Xie, Jiang, Shuler, & Bartlett, 2013). 
Native biomaterials derived from the extracellular matrix, such as collagen and fibrin, are 
also in common use. Silk fibroin, a native biomaterial, has the best elastic modulus and tensile 
strength among all natural scaffolds for cell support and tissue ingrowth (Kuo et al., 2010). 
Extracellular matrix derived from decellularized cartilage has also been studied to provide a more 
homogenous and porous scaffold for cartilage tissue engineering (Rothrauff et al., 2018). 
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1.2.3  Bioactive Factors 
Bioactive factors are critical in regulating the differentiation of stem cells to target cell 
lineages. These factors, for cartilage tissue engineering, predominantly are within transforming 
growth factor beta (TGF) superfamily.  
For applications in skeletal soft tissues, the most commonly used biologics are platelet-rich 
plasma (PRP), platelet-rich fibrin (PRF), and the orthokines. PRP, isolated from human whole 
blood as a cocktail of growth factors released from activated platelets, has been used in clinics 
since the 1990s. Although the use of PRP treatment for tissue healing and regeneration has become 
clinically popular in the last decade, scientific evidence remains insufficient with many conflicting 
results reported on its efficacy. Several reasons contribute to the observed variability, including 
variations in PRP composition, cellularity of the damaged or diseased target tissue, and the lack of 
controlled studies. Several trials have reportedly focused on assessment of PRP effects compared 
to placebo controls. In the next section, platelet biology and use of PRP will be discussed in detail. 
PRF, also called fibrin clot, is used to improve tissue regeneration as well. The use of PRF 
is considered more desirable than the use of PRP since bovine thrombin and anticoagulants are not 
required.  A commercial product, Orthokine, is based on autologous serum generated by incubating 
venous blood with etched glass beads, thus allowing peripheral blood leukocytes to produce 
elevated amounts of the interleukin-1 receptor antagonist and other anti-inflammatory mediators 
that are recovered in the serum (36).  Orthokine has been used in various applications to treat knee 
osteoarthritis; however, the effectiveness of orthokine, which is not FDA-approved, is unclear, and 
no controlled clinical trials are ongoing. 
Cartilage tissue engineering involves cells, biomimetic scaffolds, and bioactive factors 
(Figure 2). As mentioned above, the most common cell sources are bone marrow, subcutaneous 
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tissue, and infrapatellar fat pad (the focus of this dissertation). Popular biomimetic scaffolds are 
collagen, gelatin, and fibrin scaffolds. In addition, bioactive factors (e.g., transforming growth 
factors) are necessary for cartilage tissue engineering to induce and promote cartilage matrix 
deposition. 
 
 
Figure 2. Cartilage tissue engineering. 
Cartilage tissue engineering involves cells, biomimetic scaffolds, and bioactive factors. Cell sources can be 
bone marrow-derived mesenchymal stem cells (BM-MSCs), subcutaneous tissue-derived adipose stem cells (SQ-
ASCs), and infrapatellar fat pad-derived adipose stem cells (IFP-ASCs). Examples of biomimetic scaffolds are 
collagen, gelatin, and fibrin scaffolds. Bioactive factors are the key to induce proliferation (e.g., basic fibroblast 
growth factor, FGF2) and chondrogenic differentiation (e.g., transforming growth factor 3, TGF3). Adapted from 
(Ohba, Yano, & Chung, 2009). 
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Figure 3. Chondrogenic differentiation 
Chondrogenic differentiation begins with mesenchymal stem cells undergoing condensation, 
chondroprogenitors expressing SOX9, maturation of chondrocytes (expression of COL2 and ACAN), and terminal 
differentiation – hypertrophic chondrocytes (expression of COL10, MMP13, RUNX2, IHH, and VEGF). Proteins 
that are highly expressed during chondrogenic differentiation are collagen type II and IX and aggrecan; once the 
cells become hypertrophic, cells start to produce collagen type X and matrix metalloproteinase 13. Adapted from 
(Zuscik et al., 2008). 
1.3 Platelet-Rich Plasma 
Platelet-rich plasma (PRP) has recently received considerable attention as a potential 
therapeutic agent for cartilage repair, due to its cost-effective and autologous nature. PRP contains 
many growth factors and inflammatory mediators that are released from activated platelets, and it 
has been shown to promote stem cell proliferation and tissue regeneration. We expect that the 
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combination of IFP-ASCs and autologous PRP can overcome the challenge of limited cell number 
and cell expansion given the proliferative capabilities of IFP-ASCs and the growth factors in PRP.  
1.3.1  Platelet Biology 
Platelets are essential to wound healing given their function of providing primary 
hemostasis and coagulation. Specifically, when an injury occurs, the clotting cascade generates 
active thrombin from pro-thrombin, thrombin activates platelets and releases fibrinogen. 
Fibrinogen reacts with thrombin or calcium and forms fibrin clots. The bleeding then stops, i.e., 
hemostasis.  
Within platelets, there are alpha granules, dense granules, mitochondria, and other 
intracellular bodies (Kickler, 2006) (Figure 4). Upon platelet activation, growth factors and 
cytokines are released from alpha granules within seconds. These growth factors (e.g., platelet-
derived growth factor, epidermal growth factor, vascular endothelial growth factor) and cytokines 
(e.g., matrix metalloproteinases, interleukins) act to maintain the balance between anabolic and 
catabolic responses locally. Under physiological condition, plasminogen is activated to become 
plasmin which proteolytically degrades fibrin to produce fibrin degradation products. 
Physiologically, the concentration of platelets is 150,000-350,000 platelets per microliter in the 
peripheral blood (Kickler, 2006).  
A concentrate of platelets injected into the joint can potentially recruit reparatory cells and 
secrete growth factors and anti-inflammatory cytokines. Among all growth factors, transforming 
growth factor beta (TGF) superfamily which includes TGFs and bone morphogenetic proteins 
(BMP) is of interest. TGFs and BMPs are ligands that bind to TGF receptors, which are 
transmembrane proteins with cytosolic domains that exhibit serine/threonine kinase activity. 
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Signal transduction starts with direct activation of cytosolic Smad. TGF1 and TGF3 are known 
to promote chondrogenic differentiation for cartilage tissue engineering. However, studies have 
indicated that TGF1 may be associated with fibrosis and fibrocartilage formation in cartilage 
repair.  
Platelets also release several pro-inflammatory cytokines that have been shown to involve 
in osteoarthritis pathogenesis. Interleukin 6 (IL6), for instance, is highly upregulated in 
osteoarthritic cartilage (L. Sun, Wang, & Kaplan, 2011). In vitro, IL6 inhibits collagen type II gene 
expression, decreases proteoglycan deposition, and glycosaminoglycan/DNA content in BM-MSC 
cultures (Pricola, Kuhn, Haleem-Smith, Song, & Tuan, 2009). IL6 and soluble IL6 receptor alpha 
result in concentration-dependent increases in cartilage matrix deposition and collagen type II, 
aggrecan, and collagen type X gene expression in MSC pellet cultures (Kondo et al., 2015). IL6 
trans-signaling requires soluble IL6 receptor and is potentially active in all cells of the body since 
all cells express the gp130 protein (Rose-John, 2012). 
Another pro-inflammatory cytokine – interleukin 1 beta (IL1) is of interest as well. PRP 
decreases IL1-induced expression of TIMP1 and ADAMTS5 in cartilage and expression of 
TIMP1, ADAMTS, and VEGF in synovium, suggesting that PRP has anti-inflammatory effect on 
gene expression (Osterman et al., 2015). IL1 decreases COL2 and ACAN expression and 
increases ADAMTS4 and PTGS2 expression; PRP reverses IL1-induced effects suggesting PRP 
has anti-inflammatory effect (van Buul et al., 2011). IL1 significantly decreased cartilage matrix 
accumulation and decreased Young’s modulus in bovine cartilage rings centrally embedded with 
chondrocyte-encapsulated agarose hydrogels (Djouad, Rackwitz, Song, Janjanin, & Tuan, 2009). 
IL1 alone or in combination with TNFα increase collagenase and aggrecanase production and 
also suppress chondrocyte synthesis of aggrecan and collagen type II (L. Sun et al., 2011). 
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Combination of IL1 and TNFa significantly upregulates MMP1, MMP3, MMP13. ADAMTS4, 
and ADAMTS5 gene expression while downregulating ACAN (L. Sun et al., 2011). Interestingly, 
one study has shown that pre-treatment of IL1 for 14 days prior to pellet culture can increase the 
wet weight of synovium-derived MSC pellets (Matsumura et al., 2017). 
Unfortunately, PRP is currently not regulated by the United States Food and Drug 
Administration (FDA). In principle, according to FDA regulations, PRP is considered, by 
definition, a blood-derived biologic and should be regulated by the Center for Biologics Evaluation 
and Research (CBER) (Beitzel et al., 2015). However, the commercially available PRP Preparation 
Devices, such as Arthrex ACP and Zimmer Biomet GPS, are released to the market via a different 
pathway - the 510(k) clearances. Such devices are determined to be “substantially equivalent” to 
a previously cleared device. For example, one of the PRP Preparation Devices – Arthrex ACP is 
meant to be mixed with the Arthrex BioCartilage in a clinical setting. This PRP product is not for 
direct injections but mixed with autologous or allogeneic bone grafts to enhance bone repair. For 
direct injections, PRP is considered “off-label” which refers to the devices that are not FDA-
regulated; any manipulation, including platelet activation or addition of exogenous factors, is not 
yet allowed in the clinics. The main challenge of regulating PRP is that there is no consensus of 
which protocol is the best, and the number of platelets varies based on the individual difference 
among the patients, the timing of blood draw, and timing of PRP isolation given its autologous 
nature. 
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Figure 4. PRP composition and function.  
Typically, after the first spin of whole blood, three layers are plasma (approximately 55% v/v) on top, buffy coat in the 
middle (1%) which is enriched in platelets and leukocytes, and erythrocytes (45%) on the bottom. Within platelets, there are 
dense granules and alpha granules. When the platelet is activated, anabolic growth factors, anti-inflammatory factors, and 
fibrinogen that can provide scaffolding effect are released from alpha granules. 
 
1.3.2  Platelet-Rich Plasma for Pain Relief 
Clinical studies have shown that PRP treatment improves pain management and 
inflammation in osteoarthritis (Andia & Maffulli, 2013). In a randomized controlled trial in Spain, 
three injections of PRP (n = 110 patients) significantly reduced pain and stiffness scores with 
increased physical function (Sánchez et al., 2012).  
Similarly, intra-articular PRP injections (n = 60 patients) significantly improved mean 
Western Ontario and McMaster (WOMAC) score in gonarthrosis at 24 weeks, which is an 
indication of pain reduction and improved joint function, when compared to intra-articular 
hyaluronic acid injections (n = 60 patients) reported in a randomized controlled trial in Italy (Cerza 
et al., 2012).  
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PRP has been compared to placebo (saline) in a clinical trial in India (Patel, Dhillon, 
Aggarwal, Marwaha, & Jain, 2013). Single injection and double injections of PRP significantly 
improve pain, stiffness, and physical function when compared to single injection of saline at six 
months follow-up (Patel et al., 2013).  
The anti-inflammatory effects of PRP may be partially attributed to the release of anti-
inflammatory mediators from activated platelets and reduced canonical nuclear factor kappa B 
(NFkB) signaling (T. Lawrence, 2009). Anti-inflammatory mediators include interleukin 1 
receptor antagonist, soluble tumor necrosis factor receptor, interleukin 4, interleukin 10, 
interleukin 13, and interferon gamma (Xie, Zhang, & Tuan, 2014). These factors can act to block 
the receptor and downstream signaling of  IL1β or tumor necrosis factor alpha (TNFα), consistent 
with other studies that show that PRP decreases catabolic gene expression and protein secretion. 
Previously, van Buul et al. showed PRP decreased expression of catabolic markers ADAMTS4 
and COX2 on human chondrocytes within 48 hours (van Buul et al., 2011). PRP was able to rescue 
human nucleus pulposus cells from the IL1β and TNFα-induced expression of catabolic markers 
MMP3 and COX2 at 48 hours (H.-J. Kim et al., 2014). Osterman et al. also demonstrated that PRP 
was able to decrease expression of catabolic markers TIMP1 and ADAMTS5 as well as angiogenic 
marker VEGF within 72 hours on human cartilage explants (Osterman et al., 2015). 
1.3.3  Platelet-Rich Plasma for Cartilage Repair 
However, while some studies have reported pain reduction and improvement of joint 
function with PRP treatment (Bayar et al., 2008), others have found no 
improvement in cartilage formation (Brehm et al., 2006; Elizaveta Kon et al., 2010). Variations in 
PRP effectiveness include individual difference and PRP preparation which results in varied 
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growth factor/cytokine profile. Among all growth factors within PRP, studies have indicated that 
vascular endothelial growth factor (VEGF) may impair chondrogenesis and cartilage repair. More 
specifically, VEGF-transduced muscle-derived stem cells performed poorly in chondrogenesis, 
and a catabolic role of VEGF on matrix degeneration has been reported in a rat model (Kubo et 
al., 2009b; Matsumoto et al., 2009). When combined with soluble receptor to block VEGF 
signaling, soluble receptor-treated group had more collagen type II deposition in pellet culture 
(Mifune et al., 2013). Intravenous administration of anti-VEGF antibody improved articular 
cartilage repair in a rabbit model (Nagai et al., 2010). Taken together, results from these studies 
suggest that VEGF may impair the pro-chondrogenic potential of PRP. 
1.4 Research Overview 
The central hypothesis of this dissertation research is that PRP can modulate IFP-ASC 
chondrogenesis, and that removal of VEGF can further enhance IFP-ASC chondrogenesis for 
cartilage tissue engineering. The hypothesis was tested through the following specific aims: 
 
Specific Aim 1: Characterization of the effect of PRP on IFP-ASC chondrogenesis in both 
pellet and hydrogel cultures; 
Specific Aim 2: Assessment of the effect of VEGF as a component of PRP and cellular 
mechanism of VEGF action on IFP-ASC chondrogenesis; 
Specific Aim 3: In vivo application of PRP in combination with ASCs encapsulated in a 
3-dimensional hydrogel in a rabbit model of cartilage repair. 
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The studies in Aim 1 examined the general role of PRP on IFP-ASC chondrogenesis; 
studies in Aim 2 examined the effect of VEGF as a component of PRP on IFP-ASC 
chondrogenesis; and studies in Aim 3 further tested the optimized PRP on osteochondral defect 
repair in vivo. These studies together can provide information on the potential application of PRP 
in combination with cell-based therapy for cartilage repair. Our goal is to develop a point-of-care 
application for the population with post-traumatic and focal cartilage defects, ultimately restoring 
their joint function and improving the quality of life. 
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2.0 Effect of Platelet-Rich Plasma on Chondrogenic Differentiation of Adipose- and Bone 
Marrow-Derived Mesenchymal Stem Cells 
2.1 Introduction 
Cartilage degeneration affects 27 million people in the United States, and post-traumatic 
and focal cartilage defects comprise 12% of all cases (approximately 3 million Americans 
annually) (Brown, Johnston, Saltzman, Marsh, & Buckwalter, 2006; R. C. Lawrence et al., 2008).3 
Current surgical techniques for treating focal cartilage defects include osteochondral 
autograft/allograft transplantation, microfracture, and autologous chondrocyte implantation (ACI). 
In ACI, autologous chondrocytes are isolated from non-weight-bearing cartilage, expanded in ex 
vivo cultures, and returned to the chondral defect as a cell suspension covered with a periosteal 
membrane (Brittberg et al., 1994, 1996). More recently, matrix-assisted ACI (MACI) has been 
developed. In MACI, for which there are now several variations, autologous chondrocytes are 
seeded within a three-dimensional (3D) scaffold before implantation, potentially enabling better 
integration with the surrounding native cartilage while also providing a biomimetic 
microenvironment capable of enhancing cartilage neotissue formation (Freymann et al., 2013; E 
Kon et al., 2013; Makris et al., 2015).  Although both ACI and MACI have shown promise, 
challenges still persist. Chondrocyte yield from non-weight-bearing cartilage is low, requiring ex 
                                                 
3 This chapter contains materials from - Liou, J. J., Rothrauff, B. R., Alexander, P. G., & Tuan, R. S. (2018) 
Effect of platelet-rich plasma on chondrogenic differentiation of adipose- and bone marrow-derived mesenchymal 
stem cells. Tissue Engineering Part A 
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vivo cell expansion, with an accompanying loss of the chondrogenic phenotype (Tuan et al., 2013). 
As a result, the patient must undergo two surgical procedures, and the quality of cartilage repair 
remains inconsistent. Identification of alternative cell sources and application of improved 
chondroinductive conditions are needed to overcome these challenges, permitting a single-step 
procedure with robust cartilage formation. 
Adult tissue-derived mesenchymal stem cells (MSCs) are capable of undergoing 
chondrogenic differentiation and have traditionally been isolated from the iliac crest, an invasive 
procedure that yields a relatively low percentage of MSCs. Alternatively, adipose tissue contains 
a higher percentage of MSCs, is abundantly available, and can be harvested through a minimally 
invasive lipoaspiration procedure (Hildner et al., 2015). However, MSCs derived from adipose 
tissue, adipose stem cells (ASCs), have been reported as less chondrogenic than MSCs derived 
from bone marrow (BM-MSCs) (Alegre-Aguarón et al., 2012; Kohli et al., 2015). Recently, the 
infrapatellar fat pad, readily accessible intra-operatively during arthroscopic and open knee 
surgeries, was examined as an alternative source of ASCs (IFP-ASCs), which were shown to 
possess a greater chondrogenic potential than subcutaneous ASCs (SQ-ASCs) (Lopa et al., 2014). 
Specifically, it was reported that IFP-ASCs were superior to SQ-ASCs in terms of sulfated 
glycosaminoglycan (GAG) deposition and chondrogenic gene expression, with higher gene 
expression levels of aggrecan, SOX9, and collagen type II, and lower levels of collagen types X 
and I. However, the total cell number of IFP-ASCs is more limited compared to SQ-ASCs due to 
smaller tissue volume. Therefore, ex vivo culture expansion of IFP-ASCs would likely be required 
to obtain a sufficient cell number for implantation. 
Alternatively, a strategy that promotes in situ proliferation and chondrogenic 
differentiation of IFP-ASCs could provide a single-step treatment for chondral defects. Platelet-
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rich plasma (PRP), derived from whole blood, contains a large number of growth factors, and has 
been shown to promote stem cell proliferation and neotissue formation in cartilage defects (Xie et 
al., 2014).  In vivo, a number of studies have reported pain reduction and improvement of joint 
function with PRP treatment (Patel et al., 2013), while others have found no improvement in 
cartilage formation (Brehm et al., 2006; Elizaveta Kon et al., 2010).  The effect of PRP on 
chondrogenic differentiation of MSCs in vitro is also equivocal (J. K. Lee, Lee, Han, Seong, & 
Lee, 2014; Xie et al., 2012), with recent findings suggesting that the effects are dependent on PRP 
concentration (do Amaral et al., 2015).  The purpose of this study was to evaluate the effect of 
different PRP concentrations and exposure durations on proliferation and in vitro chondrogenic 
differentiation of IFP-ASCs and BM-MSCs when cultured as pellets or within a 3-dimensional 
(3D) hydrogel biomaterial scaffold. 
2.2 Methods 
2.2.1  Materials and Reagents 
All chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless 
indicated otherwise. 
2.2.2  PRP Releasate Preparation 
PRP releasate was prepared according to an adapted protocol (J. Zhang & Wang, 2010).  
Briefly, anticoagulated human whole blood (Central Blood Bank, Pittsburgh, PA) was distributed 
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into 15 mL conical tubes and centrifuged at 480 x g for 20 minutes. Pelleted red blood cells were 
discarded and the supernatant (including the buffy coat) was aspirated and concentrated to obtain 
a platelet concentration of 1x106 platelets/μL. To activate platelets, concentrated CaCl2 was added 
to a final concentration of 22.8 mM, followed by incubation at 37 C overnight. After another 
centrifugation at 2,000 x g for 10 minutes, the fibrin clot was discarded and the supernatant, 
referred to as PRP releasate, was stored at -20 oC until future use (Figure 5). According to the 
Platelet Activation White blood cells (PAW) classification system, the PRP releasate prepared here 
was categorized as P3-X-Aα (Delong, Russell, & Mazzocca, 2012). Before use in experiments, 
equal volumes of PRP releasate from three donors were pooled. 
 
 
Figure 5. PRP releasate preparation. 
(A) Anti-coagulated human whole blood was distributed into 15 mL conical tubes and centrifuged at 480 x 
g for 20 minutes. (B) The pelleted red blood cells (RBC) were discarded and the supernatant containing platelet-
poor plasma (PPP) and buffy coat (BC) was partially aspirated to obtain a platelet concentration of 1 x 106 
platelets/uL. To activate platelets, 22.8 mM calcium chloride was added and incubated at 37 oC overnight. (C) After 
another centrifugation at 2,000 x g for 10 minutes, the fibrin clots (FC) were discarded. (D) The resulting 
supernatant was referred to as PRP releasate and frozen for future use. 
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2.2.3  Cell Isolation 
All adult human cells were isolated according to Institutional Review Board (IRB) 
approved protocols (University of Washington and University of Pittsburgh). 
Human IFP-ASCs were isolated from infrapatellar fat pads of three different donors 
undergoing total knee arthroplasty (48 years old female, 59 years old male, and 65 years old male). 
The tissue was digested with 1 mg/mL type I collagenase (Worthington Biochemical, Lakewood, 
NJ) and 1 mg/mL trypsin (Invitrogen, Carlsbad, CA) for 3 hours at 37 C in an orbital shaker at 150 rpm. 
Cells were filtered through a 40 m cell strainer (ThermoFisher, Pittsburgh, PA), pelleted by 
centrifugation at 1,200 rpm for 5 minutes, and expanded in growth medium (GM: Dulbecco’s 
Modified Eagle’s Medium [DMEM; Invitrogen], 10% v/v fetal bovine serum [FBS; Gemini Bio 
Product, West Sacramento, CA] and 1% v/v antibiotic-antimycotic [Invitrogen]).  
Human subcutaneous ASCs (SQ-ASCs) were isolated from lipoaspirate-derived fat tissue 
of three donors (34 years old male, 38 years old female, and 49 years old female) using an 
automated cell isolation system (Icellator, Tissue Genesis, Honolulu, HI). Cells were pelleted by 
centrifugation and culture-expanded in GM. 
Human BM-MSCs were isolated from the bone marrow of three different patients 
undergoing arthroplasty (65 years old male, 67 years old male, and 68 years old male). Briefly, the 
trabecular bone marrow was rinsed with Minimum Essential Medium alpha (αMEM; Invitrogen) 
containing 1% v/v antibiotic-antimycotic and filtered through 40 m strainers. Cells were pelleted 
by centrifugation and culture-expanded in GM.  
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2.2.4  Cell Characterization 
The presence of surface markers, including CD31, CD34, CD44, CD45, CD73, CD90, and 
CD105, in SQ-ASCs and IFP-ASCs was assessed by flow cytometry using appropriate monoclonal 
antibodies (mouse anti-human antibodies; BD Biosciences, San Jose, CA).  
2.2.5  Colony Formation Assay 
Colony formation was analyzed by crystal violet staining. Briefly, cells were cultured as 
monolayers on 10-cm Petri dishes (ThermoFisher, Pittsburgh, PA) at a seeding density of 100 cells 
per dish in GM for 14 days. On day 14, monolayer cultures were stained with 0.5% crystal violet 
(Sigma-Aldrich) in 100% methanol (ThermoFisher) for 10 minutes prior to imaging.  
2.2.6  Differentiation Assay 
Monolayer Cultures  Tri-lineage differentiation of SQ-ASCs and IFP-ASCs was analyzed 
via monolayer culture in, respectively: (1) chondrogenic medium (DMEM, 1% v/v antibiotic-
antimycotic, 1x insulin-transferrin-selenium [ITS; ThermoFisher #41400045], 0.1 μM 
dexamethasone, 40 μg/mL proline, 50 μg/mL ascorbic acid, and 10 ng/mL recombinant human 
transforming growth factor-β3 [PeproTech #100-36E, Rocky Hill, NJ]; (2) osteogenic medium 
(DMEM, 10% v/v FBS, 1% v/v antibiotic-antimycotic, 0.1 μM dexamethasone, 10 mM β-
glycerophosphate, and 50 μg/mL ascorbic acid); and (3) adipogenic medium (DMEM, 10% v/v 
FBS, 1% v/v antibiotic-antimycotic, 1x ITS, 1 μM dexamethasone, and 0.5 mM 3-isobutyl-1-
methylxanthine [IBMX]).  On day 21, the cultures were stained with Alcian Blue, Alizarin Red, 
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and Oil Red O, using standard histological staining protocols, to assess chondrogenesis, 
osteogenesis, and adipogenesis, respectively. 
High Density Pellet Culture  Chondrogenesis was also examined under conditions that 
mimic mesenchymal condensation during developmental cartilage formation as high-density pellet 
cultures. 2.5 x 105 IFP-ASCs or BM-MSCs were pelleted by centrifugation, and then maintained 
in serum-free chondrogenic medium. The effect of PRP on chondrogenesis was measured by 
varying PRP concentration or exposure duration as follows: (1) pellets were cultured for 21 days 
in chondrogenic medium, which was supplemented with 10% v/v PRP releasate for the initial 0, 
1, 3, 7, or 21 days (referred to as 1-, 3-, 7, or 21-day pulse, respectively); and (2) pellets were 
cultured for 21 days in chondrogenic medium, which was supplemented with PRP releasate at 0, 
1, 5, 10, or 20% v/v for the first 24 hours. The 24-hour exposure to PRP was intended to mimic 
the transient bolus of growth factors provided by a single intraarticular injection of PRP, as 
commonly employed in clinical practice (Campbell et al., 2015). Culture medium was regularly 
changed three times a week, except for medium changes dictated by a particular PRP exposure 
duration indicated above.  
2.2.7  Three-Dimensional Hydrogel Culture 
We next examined the effect of PRP on MSC chondrogenesis in a 3D context more relevant 
to the translational application of MSCs in cartilage repair-based cartilage repair. MSCs were 
encapsulated in photocrosslinkable hydrogels previously shown to support robust chondrogenesis 
(H. Lin, Cheng, Alexander, Beck, & Tuan, 2014). Visible-light-activated methacrylated gelatin 
(mGL)/methacrylated hyaluronic acid (mHA) hydrogels were fabricated as described previously 
(H. Lin, Lozito, Alexander, Gottardi, & Tuan, 2014). Briefly, 15 g of gelatin (Sigma-Aldrich) was 
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dissolved in 500 mL H2O at 37°C, and 15 mL of methacrylic anhydride (Sigma-Aldrich) was 
added dropwise. The mixture was incubated with shaking at 150 rpm for 24 hours, then dialyzed 
against water for 4 days, and mGL lyophilized for storage.  The photoinitiator, lithium phenyl-
2,4,6-trimethylbenzoylphosphinate (LAP), was prepared as described by Fairbanks et al. 
(Fairbanks, Schwartz, Bowman, & Anseth, 2009). For mHA, 5 gram of sodium hyaluronate (66 
kDa, Lifecore Biomedical, Chaska, MN) was dissolved in 500 mL H2O at 37°C, and 15 mL of 
methacrylic anhydride was added dropwise. At the end of every hour in the first 5 hours, pH was 
adjusted to 7.  The mixture was then incubated with shaking at 150 rpm for 24 hours, dialyzed 
against water for 4 days, and lyophilized for storage. For hydrogel fabrication, mGL and mHA 
were dissolved in Hank’s Balanced Salt Solution (HBSS) at final concentrations of 9% and 1% 
(w/v), respectively. After adjustment of pH to 7.4 with 10 N NaOH, 1% antibiotic-antimycotic and 
0.15% w/v LAP were added.  IFP-ASC or BM-MSC pellets were resuspended in mGL/mHA 
solution at a final concentration of 15 x 106 cells/mL, and 50 L of the suspension was transferred 
to a cylindrical mold measuring 5 mm diameter by 2 mm depth. The cell/monomer mixture was 
subjected to photoillumination (395 nm) for 90 seconds, forming a cell encapsulated mGL/mHA 
hydrogel. Constructs were cultured in Phenol Red-free chondrogenic medium supplemented with 
different PRP releasate concentrations (0, 1, 5, 10, and 20% v/v) for 21 days. Culture medium was 
changed twice a week. 
2.2.8  Gene Expression Analysis 
Both pellet and hydrogel cultures were collected on day 21, homogenized in Qiazol 
(Qiagen, Hilden, Germany), and total RNA isolated with RNeasy Plus Mini Kit (Qiagen). Gene 
expression levels of chondrogenesis markers (collagen type II, COL2; aggrecan, ACAN) and 
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hypertrophy markers (collagen type X, COL10; matrix metalloproteinase 13, MMP13) were 
assessed by real-time RT-PCR and normalized to that of 18S ribosomal RNA (gene primers 
sequences shown in Table S2). Relative fold changes in mRNA levels were calculated using the 
ΔΔCt method.  
2.2.9  Histological Analysis  
Pellets and hydrogels collected on culture day 21 were fixed with 4% phosphate-buffered 
paraformaldehyde, dehydrated, and embedded in paraffin. Histological sections (8 m) were 
stained with Safranin O/Fast Green and Alcian Blue/Nuclear Fast Red for sulfated GAG. For 
collagen type II immunohistochemistry, deparaffinized sections were washed with 0.02% bovine 
serum albumin and incubated with 0.1 U/mL chondroitinase ABC and 250 U/mL hyaluronidase 
for antigen retrieval, followed by blocking with 3% H2O2 in 1% horse serum. Sections were then 
incubated with rabbit anti-human collagen type II (Abcam #ab34712, Cambridge, UK) at 4 °C 
overnight, and then with biotinylated anti-rabbit secondary antibody. Immunolabeling was 
detected using the Vector ABC reagent (Vector, Burlingame, CA) and visualized with VIP Kit 
(Vector), with hematoxylin QS (Vector) as the counter-stain. 
2.2.10  Biochemical Analysis 
Pellet cultures were digested overnight at 65 °C in a digestion buffer (pH 6.0) containing 
2% (v/v) of a commercially available papain solution (v/v, from Papaya latex, Sigma-Aldrich, 
containing 15-30 mg protein/ml with > 16 units/mg), 0.1 M sodium acetate, 10 mM cysteine HCl, 
and 50 mM EDTA. Sulfated GAG content was measured with the Blyscan GAG Assay (BioColor, 
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Carrickfergus, UK) according to the manufacturer’s instructions, with chondroitin sulfate as a 
standard. GAG content was normalized to DNA content determined with PicoGreen Assay 
(Invitrogen).  
2.2.11  Statistical Analysis 
Values of gene expression levels, GAG contents, and DNA contents are shown as mean  
standard deviation. Three to six independent trials were performed for each experiment. Statistical 
difference from control (No PRP group) was analyzed by one-way ANOVA and Dunnett’s 
multiple comparisons using GraphPad Prism 7 (GraphPad Software Inc, CA), with significance at 
p < 0.05.  
2.3 Results 
2.3.1  Comparison of IFP-ASCs and SQ-ASCs 
In this study, ASCs obtained from both the infrapatellar fat pad (IFP-ASCs) and 
subcutaneous lipoaspirate (SQ-ASCs) were used. Both cell populations were confirmed by flow 
cytometry to exhibit MSC-associated surface markers. Positive expression of cell surface markers 
typical of adult MSCs, such as those derived from bone marrow (BM-MSCs), including CD44, 
CD73, CD90, and CD105, was detected, with negligible expression of epithelial and hematopoietic 
markers, including CD31, CD34, and CD45 (Figure 6A). In addition, IFP-ASCs and SQ-ASCs 
were both able to form colonies and differentiate into adipogenic, osteogenic, and chondrogenic 
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lineages (representative images shown for IFP-ASCs in Figure 6B).  The chondrogenic capacity 
of ASCs isolated from the infrapatellar fat pad (IFP-ASCs) and subcutaneous lipoaspirate (SQ-
ASCs) was next compared. Pellet cultures consisting of 2.5 x 105 IFP-ASCs or 2.5 x 105 SQ-ASCs 
each were maintained in chondrogenic medium. At culture day 21, the RT-PCR analysis showed 
that gene expression level of SOX9 and COL2 was significantly higher in the IFP-ASC pellets 
than in the SQ-ASCs pellets (Figure 7). Taken together, these results indicate the preferred 
chondrogenic ability of IFP-ASCs over SQ-ASCs, and their relevance as a candidate cell type for 
cell-based cartilage repair therapy. 
  
 33 
 
Figure 6. Characteristics of monolayer cultured IFP-ASCs. 
(A) Surface marker profile.  High mesenchymal stem cell characteristics of IFP-ASCs, similar to BM-
MSCs and SQ-ASCs, is indicated by high expression of CD44, CD73, CD90, and CD105, and negligible expression 
of CD31, CD34, and CD45. (B) Colony formation ability and tri-lineage multipotent differentiation of IFP-ASCs. 
Colony formation was detected by Crystal Violet staining (bar = 2 cm), and monolayer cultures of IFP-ASCs 
undergoing chondrogenesis, osteogenesis, and adipogenesis were assessed histologically by Alcian blue, Alizarin 
Red, and Oil Red O staining (bar = 2 mm). 
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Figure 7. Comparison of IFP-ASCs and SQ-ASCs. 
(A) SOX9 gene expression of IFP-ASCs treated with TGFβ3 shows higher expression level when 
compared to SQ-ASCs with or without TGFβ3 at day 21. At day 7, IFP-ASCs are significantly superior to SQ-
ASCs. (B) COL2 gene expression of IFP-ASCs shows higher expression level when compared to SQ-ASCs at day 
21. *, p < 0.05 
  
2.3.2  Effect of PRP on chondrogenic differentiation in pellet culture 
Gross histological observation revealed that the overall influence of PRP exposure was the 
inhibition of cartilage matrix deposition in IFP-ASC pellet cultures, as shown in Figures S2 and 
S3.  Specifically, increasing PRP concentrations or duration individually, as well as additively, 
reduced chondrogenesis.  To examine the specific effects of PRP, we profiled gene expression, 
analyzed the biochemical composition, and carried out histological and immunohistochemical 
examination of pellet cultures during the process of IFP-ASC chondrogenesis, as a function of 
PRP concentration and treatment duration.   
Varying duration of PRP treatment  Pellet cultures of BM-MSCs and IFP-ASCs maintained 
in chondrogenic medium were supplemented with 10% v/v PRP releasate for varying time periods 
during the 21-day culture.  As shown in Figure 2, the magnitude of the PRP effect, i.e., inhibition 
of chondrogenesis, depending on the duration of treatment. Increasing the duration of PRP 
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exposure resulted in decreased expression of COL2, ACAN, and COL10, with negligible effects 
on MMP13 expression, in IFP-ASCs (Figure 8A).  Varying duration of PRP treatment did not 
affect cell number, on the basis of dsDNA content, in either IFP-ASC or BM-MSC pellets; 
however, increasing PRP treatment time resulted in decreasing GAG/DNA content in IFP-ASCs, 
but not in BM-MSCs (Figures 8B, 9A). This effect was supported by histological staining, as 
increasing duration of PRP supplementation led to decreasing deposition of cartilage-specific 
extracellular matrix in IFP-ASC pellets, including sulfated GAG and collagen type II (Figure 2C). 
As a result, the size of the pellet decreased as PRP concentration or treatment duration increased. 
In BM-MSC pellets, some decrease in cartilage extracellular matrix production was also observed, 
although the inhibitory effect of PRP was not as strong (Figure 9B). 
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Figure 8. Effect of treatment with 10% PRP for varying durations on IFP-ASC pellet cultures. 
(A) Gene expression of IFP-ASCs in 21-day pellet culture. RT-PCR analysis showed longer exposure to 
PRP resulted in higher reduction of expression of collagen type II, aggrecan, and collagen type X, while expression 
of MMP13 was unchanged. (B) DNA and GAG content of IFP-ASCs in 21-day pellet culture. No change in DNA 
content was seen in the various treatment groups, while normalized GAG content decreased with longer exposure to 
PRP releasate.  *, p < 0.05; ns, not significant. (C) Histology of IFP-ASCs in 21-day pellet culture. Longer PRP 
exposure time resulted in higher reduction in matrix proteoglycan histological staining, as well as reduced collagen 
type II content detected by immunohistochemistry. Bar = 400 µm. 
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Figure 9. Effect of treatment with 10% PRP for varying durations on BM-MSC pellet cultures. 
(A) DNA and GAG content of BM-MSC in 21-day pellet culture. No difference in DNA and normalized 
GAG contents was seen in the various treatment groups. *, p < 0.05; ns, not significant. (B) Histology of BM-MSCs 
in 21-day pellet culture. No difference was seen in histological staining of matrix proteoglycan or 
immunohistochemically detected collagen type II was observed. Bar = 400 µm. 
 
Varying PRP concentration  For this study, transient PRP exposure, as in clinical intra-
articular injections (Campbell et al., 2015), was simulated by exposing pellet cultures to PRP 
releasate supplementation only for the first 24 hours of the 21-day culture period. In IFP-ASC 
pellets, gene expression profile remained relatively unchanged among the treatment groups 
exposed to different PRP concentrations (Figure 10A), except that at low, 1% PRP, increased 
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cartilage matrix production and collagen type II deposition was seen, compared to cultures treated 
with higher PRP concentrations (Figure 10B). [Note: The first panel (No PRP) and the fourth 
panel (10% PRP, 1-day pulse) are repeated from Figure 2C.] In BM-MSC cultures, gene 
expression of COL2, ACAN, and MMP13 remained unchanged upon treatment with different PRP 
concentrations for 1 day; however, the hypertrophy associated gene, COL10, was significantly 
upregulated upon treatment with 20% PRP (Figure 11A). Matrix sulfated GAG staining with 
Safranin O and Alcian Blue appeared similar in the various groups, except for 20% PRP, which 
showed slightly reduced staining intensity (Figure 11B). Figure 12 and Figure 13 summarize the 
Safranin O and Alcian Blue staining of IFP-ASC pellets with different PRP concentrations for 
varying duration. 
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Figure 10. Effect of 1-day pulse PRP at varying concentrations on IFP-ASC pellet cultures. 
(A) Gene expression profile. No significant difference in gene expression profile was observed in the 
different PRP treatment groups. *, p < 0.05; ns, not significant. (B) Histological analysis. PRP treatment at low 
concentration (1% PRP) and for short duration (1-day pulse) preserved matrix proteoglycan and collagen type II 
deposition. Bar = 400 µm. 
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Figure 11. Effect of 1-day pulse PRP at varying concentrations on BM-MSC pellet cultures. 
(A) Gene expression profile. Gene expression was largely unchanged in the different PRP treatment 
groups, except for the upregulation of collagen type X in the 20% PRP treatment group. *, p < 0.05; ns, not 
significant. (B) Histological analysis. No difference was observed in proteoglycan deposition and collagen type II 
production. Bar = 400 µm. 
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Figure 12. Safranin O staining of IFP-ASC pellet cultures.  
As PRP concentration or duration decreases, proteoglycan deposition increases. Bar = 400 µm. 
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Figure 13. Alcian blue staining of IFP-ASC pellet cultures. 
As PRP concentration or duration decreases, proteoglycan deposition increases.  Bar = 400 µm. 
2.3.3  Effect of PRP on chondrogenic differentiation in hydrogel culture 
Given the preferred practice of encapsulating MSCs in 3D scaffolds for cartilage tissue 
engineering and repair, we next examined the effect of PRP exposure on chondrogenesis of MSCs 
in a 3D context, specifically by seeding cells in a photocrosslinkable hydrogel. IFP-ASCs were 
encapsulated in mGL/mHA hydrogels and cultured for 21 days in chondrogenic medium, with 
PRP supplementation at different concentrations. Our results showed that, with increasing PRP 
concentrations, the relative expression of COL2, ACAN, COL10, and MMP13 was reduced 
(Figure 14A).  In comparison, BM-MSCs in hydrogel cultures showed significant reduction only 
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in COL2 and ACAN gene expression (Figure 15A). Alcian blue histological staining showed that 
PRP treatment inhibited pericellular GAG deposition (Figures 14B, 15B). 
 
 
Figure 14. Effect of 21-day PRP at varying concentrations on IFP-ASC hydrogel cultures. 
(A) Gene expression profile. Similar to pellet cultures, PRP treatment downregulated the expression of 
collagen type II, aggrecan, and collagen type X, while expression of MMP13 remained the same. *, p < 0.05; ns, not 
significant. (B) Histological analysis. Cartilage matrix deposition decreased with increasing PRP concentration. Bar 
= 1 mm & 100 µm. 
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Figure 15. Effect of 21-day PRP at varying concentrations on BM-MSC hydrogel cultures.  
(A) Gene expression. Like pellet cultures, PRP treatment downregulated the expression of collagen type II 
and aggrecan, while expression of collagen type X and MMP13 remained the same. *, p < 0.05; ns, not significant. 
(B) Histological analysis. No difference in proteoglycan deposition and collagen type II production was observed. 
Bar = 1 mm & 100 µm. 
2.4 Discussion 
PRP has received considerable recent attention as a potential therapeutic agent for tissue 
repair, including joint tissues; however, whether PRP enhances the formation of hyaline cartilage 
remains controversial. While some studies have reported pain reduction and improvement of joint 
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function with PRP treatment (Patel et al., 2013), others have reported no improvement of cartilage 
repair in in vivo models (Brehm et al., 2006; G. Filardo et al., 2015; Giuseppe Filardo et al., 2012; 
Elizaveta Kon et al., 2010; Xie et al., 2014). In this study, our results clearly showed that PRP did 
not enhance chondrogenesis of IFP-ASC and BM-MSC in vitro.  
For adult stem cell therapy, BM-MSC is considered the gold-standard candidate cell type, 
by virtue of the large body of information currently available on its biological activities and 
responses (Haleem et al., 2010; Milano et al., 2010; Xie et al., 2012). However, the biological 
benefits of PRP treatment on BM-MSC, for the purpose of tissue repair and regeneration, are not 
well understood and remain controversial.  For example, Haleem et al. reported a case study that 
all patients showed improvement 12 months after treatment of autologous BM-MSCs along with 
fibrin-containing PRP (Haleem et al., 2010). However, the advantage of PRP treatment was not 
observed in a porcine model. Betsch et al. reported that PRP alone or BM-MSC alone significantly 
improved healing of osteochondral defects 26-week after surgery, but the combination of PRP and 
BM-MSCs did not further enhance wound healing (Betsch et al., 2013). In studying the efficacy 
of combining PRP and BM-MSC, do Amaral et al. reported that higher concentration of PRP 
actually impaired chondrogenesis of BM-MSC in pellet cultures (do Amaral et al., 2015).  
In this study, we investigated the effect of PRP on BM-MSC in both pellet and 3D hydrogel 
cultures, the latter to better recapitulate the microenvironment of MSCs encapsulated in 3D 
biomaterial scaffolds for clinical tissue repair applications. In both types of cultures, treatment 
dose and durations were varied to assess biologically optimal conditions. At 10% PRP, which 
approximates PRP concentrations used for intra-articular injections (Pourcho, Smith, Wisniewski, 
& Sellon, 2014), varying treatment durations (from 1-day pulse to 21-day pulse continuous 
treatment) did not yield significantly different results in pellet cultures, although PRP treatment 
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for the first 24 or 72 hours seemed to enhance GAG deposition. In hydrogel cultures, PRP 
treatment highly downregulated the expression of collagen type II and aggrecan, confirming that 
PRP does not enhance chondrogenesis in BM-MSC. While some studies have reported that PRP 
promoted cell proliferation of BM-MSCs (Mishra et al., 2009), we did not observe any PRP-
mediated increase in DNA content in any group. In support, Krüger et al. also reported similar 
findings, namely that PRP co-treatment down-regulated gene expression of aggrecan and collagen 
type II in TGFβ3-treated pellet cultures of subchondral bone progenitor cells (Krüger et al., 2012). 
IFP-ASCs, on the other hand, have not been extensively investigated in terms of their 
chondrogenic activity. Given the easy access to the IFP, for example via arthroscopic procedures, 
IFP-ASCs would present a more readily available cell source than BM-MSCs for point-of-care 
applications. We have therefore performed detailed characterization of the IFP-ASCs, in 
comparison to BM-MSCs. Our results showed that adipose tissue-derived stem cells expressed 
high levels of surface epitopes commonly detected in BM-MSCs, including CD44, CD73, CD90, 
and CD105, with negligible expression of surface markers for epithelial and hematopoietic cells, 
such as CD31, CD34, and CD45, consistent with reported findings (Amable, Teixeira, Carias, 
Granjeiro, & Borojevic, 2014; Lopa et al., 2014). Interestingly, we also observed that IFP-ASCs 
performed better regarding chondrogenesis than SQ-ASCs (Lopa et al., 2014; Pires de Carvalho 
et al., 2014).  
The chondrogenic activity of IFP-ASCs maintained in 3D biomaterial scaffolds has been 
studied, and cell proliferation and cartilage matrix deposition have been reported for cultures in 
fibrin, agarose, collagen-hyaluronic acid, and polylactic acid hydrogel in vitro (Ahearne, Buckley, 
& Kelly, 2011; Ahearne, Liu, & Kelly, 2014; Almeida et al., 2014; Y. Liu, Buckley, Almeida, 
Mulhall, & Kelly, 2014; Luo, Thorpe, Buckley, & Kelly, 2015). At present, only one study has 
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investigated the combination of IFP-ASCs and PRP. In this Level IV case study, 18 osteoarthritis 
patients were treated with autologous IFP-ASC and 3 mL of PRP as scaffold via intra-articular 
injections (Koh et al., 2013). Two-year follow-up showed promising results including pain 
reduction and joint function restoration. However, in contrast to the potential therapeutic effects 
reported by these authors, our in vitro analysis of the effects of PRP exposure on IFP-ASCs showed 
that PRP impairs chondrogenesis of IFP-ASC in both pellet and 3D hydrogel cultures. These 
contrasting findings merit some discussion regarding the potential biological benefits of using PRP 
to treat joint cartilage related pathologies. 
A major complication in assessing the clinical benefit of PRP is the high variability of PRP 
preparations and the different tissue or disease targets. PRP preparation generally involves a two-
step centrifugation: the first step fractionates platelet-poor plasma, buffy coat, and red blood cells; 
and the second step generates either leukocyte-containing PRP or pure PRP depending on which 
portion is taken (Dohan Ehrenfest, Rasmusson, & Albrektsson, 2009). In our preparation, we 
collected both the buffy coat and platelet-poor plasma, resulting in leukocyte-containing PRP, a 
practice that is used in the majority of clinical practices. In view of these variabilities in PRP 
preparation, we propose that the following parameters and caveats must be taken into account in 
considering the efficacy of PRP treatment.  
(a) PRP concentration and duration. Our results strongly suggest that PRP, when applied 
for cartilage-related treatments, must be used at low concentration and for short duration. Results 
from do Amaral et al. also showed that 2.5% PRP was better than 10% PRP applied in a 
collagen/hyaluronic acid scaffold in vitro (do Amaral et al., 2015). Other studies have also 
suggested that higher PRP concentration was not better for chondrogenesis (Gaissmaier et al., 
2005; Spreafico et al., 2009; S. Y. Yang et al., 2000). Regarding the duration of PRP treatment, 
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Park et al. reported a continuous increase of bone morphogenetic protein 7 (BMP-7) and vascular 
endothelial growth factor (VEGF), both involved in bone remodeling, in rabbit chondrocyte 
cultures exposed to continuous presence of PRP for 10 days (Park, Lee, Kim, Ahn, & Do, 2011). 
Taken together with our findings reported here, longer duration of PRP treatment very likely will 
lead to hypertrophy and bone formation. 
(b) Platelet number. In our study, we re-suspended platelets at 1.0 x 106 platelets/L before 
calcium activation. Based on the PAW (Platelet, Activation, White Cell) Classification System, 
our PRP releasate is categorized as P3 (0.75~1.25 x 106 platelets/L) (Delong et al., 2012). Of 
relevance, a recent study showed that higher platelet number (5-fold to whole blood) diminished 
pro-collagen expression in anterior cruciate ligament fibroblasts (Yoshida, Cheng, & Murray, 
2014). Taken together, these findings suggest higher platelet number is not necessarily higher 
performing for chondrogenesis.  
(c) Platelet activation. In our PRP preparation, exogenous calcium chloride was added for 
platelet activation, since it has been shown to be more effective and inexpensive than bovine 
thrombin (Textor & Tablin, 2012). Calcium reacts with fibrinogen and forms fibrin clots which 
are typically removed, resulting in PRP releasate. Dohan Ehrenfest et al. summarized current 
protocols for pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin, and leukocyte-rich PRF 
based on the speed and time of centrifugation and portion collected after centrifugation (Dohan 
Ehrenfest et al., 2009); however, a direct comparison between the four preparations in terms of 
cartilage repair was not performed. In the operating room, no exogenous platelet activation is 
required before PRP injections because collagen in the body acts as platelet agonist and activates 
platelets. 
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(d) Leukocyte number. As mentioned above, leukocyte-containing PRP was used in this 
study. Rios et al. showed that after lipopolysaccharide treatment, leukocyte-rich PRP released 
more growth factors and anti-inflammatory cytokines than pure PRP in healthy cartilage explants 
(Rios et al., 2015). In a clinical trial, patients treated with leukocyte-containing PRP suffered from 
more swelling and pain when compared to leukocyte-reduced PRP group (Giuseppe Filardo et al., 
2012). However, a prospective study of multiple clinical trials showed no significant difference 
between leukocyte-poor PRP and leukocyte-rich PRP on cartilage repair (Riboh, Saltzman, Yanke, 
Fortier, & Cole, 2015). It is possible that inflammatory cytokines released from leukocytes induce 
inflammation (swelling and pain) in the early stage, but in the long term, leukocytes do not affect 
cartilage repair. 
One of the limitations in this study is lack of information on the nature of the growth factor 
and cytokine profiles in the PRP preparation, which would vary in different preparations 
depending on the methods of platelet activation (Textor & Tablin, 2012). Specifically, the levels 
of chondrogenesis-promoting factors, such as members of the transforming growth factor-β 
(TGFβ) family, may regulate the extent of cartilage formation. Other factors, including vascular 
endothelial growth factor (VEGF) and epidermal growth factor (EGF), may also impair the 
chondro-inductive effects of PRP. Matsumoto et al. showed that VEGF-transduced, muscle 
derived stem cells performed poorly in chondrogenesis in a rat model (Kubo et al., 2009b; 
Matsumoto et al., 2009). When combined with soluble VEGF receptor 1 (sFlt1), pellet cultures of 
the sFlt1-PRP treated group showed more collagen type II deposition (Mifune et al., 2013). EGF 
receptor ligand that was identified in osteoarthritis cartilage promoted chondrocyte catabolic 
activity, but inhibited anabolic activity in a mouse model (Long, Ulici, Chubinskaya, & Loeser, 
2015). These findings suggest that VEGF or EGF, known components of PRP, may negatively 
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impact the activities of other chondro-inductive components of PRP; thus, specific depletion of 
such anti-chondrogenesis factors from PRP may enhance the pro-chondrogenesis effect of PRP on 
MSCs. 
Another limitation of our study is that a PRP releasate pooled from several donors was 
used, in order to examine the overall effects of dosage and treatment duration on MSC 
chondrogenesis for a given PRP preparation.  It is noteworthy that Mazzocca et al. reported that 
platelet and white blood cell numbers vary between individuals and repetitive withdraws of same 
individual (Mazzocca, 2012). More extensive future studies using a statistically significant number 
of PRP preparations from different donors are clearly needed to examine and correlate the 
biological activities with the variables noted above. 
2.5 Conclusion 
In 21-day IFP-ASC chondrogenic pellet cultures, high PRP concentrations delivered over 
days 7-21 increased catabolic gene expression, decreased chondrogenic gene expression, and 
decreased matrix proteoglycan deposition, compared to TGFβ+/PRP- controls. Short duration and 
low concentration PRP treatment (1-day pulse, 1% PRP) resulted in increased cartilage matrix 
production and collagen type II deposition, compared to longer durations and higher 
concentrations. Furthermore, in 21-day 3D hydrogel cultures, PRP treatment highly 
downregulated chondrogenic gene expression and decreased proteoglycan deposition, compared 
to TGFβ+/PRP- controls. These results showed that high concentration PRP treatment for 
prolonged period impairs MSC chondrogenesis in vitro. Understanding the effects of PRP on MSC 
chondrogenesis is necessary to further develop strategies for the application of PRP in combination 
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with cell-based therapy for the repair of focal cartilage defects. For example, autologous MSCs 
encapsulated in an autologous PRP-containing biocompatible hydrogel may be injected into the 
defect site, resulting in optimal MSC chondrogenic differentiation and production of cartilage 
extracellular matrix, and the formation of functional neo-cartilage. 
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3.0 Vascular Endothelial Growth Factor Impairs Pro-Chondrogenic Activity of Platelet-
Rich Plasma on Adipose Stem Cells 
3.1 Introduction 
Cartilage degeneration affects 27 million people in the United States, and post-traumatic 
and focal cartilage defects comprise 12% of all cases (approximately 3 million Americans 
annually) (Brown et al., 2006; R. C. Lawrence et al., 2008). Current surgical techniques for treating 
focal cartilage defects include osteochondral autograft/allograft transplantation, microfracture, and 
autologous chondrocyte implantation (ACI). In ACI, autologous chondrocytes are isolated from 
non-weight bearing cartilage, expanded ex vivo, and returned to the chondral defect as a cell 
suspension covered with a collagen membrane (Huang et al., 2016). More recently, matrix-assisted 
ACI (MACI) has been developed. In MACI, autologous chondrocytes are seeded within a three-
dimensional scaffold before implantation, theoretically provided better integration with the 
surrounding native cartilage while also providing a biomimetic microenvironment capable of 
enhancing cartilage neotissue formation (Freymann et al., 2013; E Kon et al., 2013; Makris et al., 
2015).  Although both ACI and MACI have shown promise, challenges persist. Donor site 
morbidity is the main challenge. Chondrocyte yield from non-weight bearing cartilage is low, 
requiring ex vivo cell expansion with an accompanying loss of the chondrogenic phenotype (Tuan 
et al., 2013). As a result, the patient must undergo two surgical procedures and the quality of 
cartilage repair remains inconsistent. Identification of alternative cell sources and the application 
of chondroinductive scaffolds are needed to overcome these challenges, permitting a single-step 
procedure with robust cartilage formation. 
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Mesenchymal stem cells (MSCs) are capable of undergoing chondrogenic differentiation 
and have traditionally been isolated from the bone marrow, a painful procedure that yields a 
relatively low percentage of MSCs. Alternatively, adipose tissue contains a higher percentage of 
MSCs, is abundantly available, and can be harvested through a minimally invasive lipoaspiration 
procedure (Hildner et al., 2015). Recently, human MSCs derived from the infrapatellar fat pad 
(IFP-ASCs) were shown to possess a greater chondrogenic potential than subcutaneous ASCs (SQ-
ASCs) (Lopa et al., 2014) and ideally provide a stem cell source in one-step procedures. However, 
the total cell number of IFP-ASCs is limited compared to SQ-ASCs due to a smaller tissue volume. 
Therefore, ex vivo culture expansion of IFP-ASCs would likely be required to obtain a sufficient 
cell number for implantation. Alternatively, it may be possible to promote IFP-ASC proliferation 
at the site of implantation, thereby allowing the intraoperative isolation of IFP-ASCs and 
implantation into a chondral defect. 
Platelet-rich plasma (PRP) has recently received considerable attention as a potential 
therapeutic agent for cartilage repair, due to its non-invasive, cost-effective and autologous nature. 
PRP contains many growth factors and inflammatory mediators that are released from activated 
platelets, and it has been shown to promote stem cell proliferation and tissue regeneration. We 
hypothesize that the combination of IFP-ASCs and autologous PRP can overcome the challenge 
of limited cell number and cell expansion given the proliferative capabilities of IFP-ASCs and the 
growth factors in PRP. However, the efficacy of PRP is controversial. Some studies have reported 
pain reduction and improvement of joint function with PRP treatment (Bayar et al., 
2008), while others have found no improvement in cartilage formation (Brehm et al., 2006; 
Elizaveta Kon et al., 2010). Variations in PRP effectiveness include timing of blood draw, 
individual difference, and preparation protocol which results in varied growth factor and cytokine 
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profiles. Among all growth factors within PRP, studies have indicated that vascular endothelial 
growth factor (VEGF) may impair stem cell chondrogenesis and cartilage repair. More 
specifically, VEGF has been shown to induce endothelial cell migration and proliferation and 
highly promote angiogenesis in vivo (Carlevaro et al., 2000).VEGF and VEGF receptors are highly 
expressed in osteoarthritis cartilage indicating that VEGF may be responsible for the degradation 
of healthy cartilage by the production of matrix metalloproteinases (Enomoto et al., 2003). VEGF-
transduced muscle-derived stem cells performed poorly in chondrogenesis and a catabolic role of 
VEGF on matrix degeneration has been reported in a rat model (Kubo et al., 2009b; Matsumoto et 
al., 2009). When combined with soluble receptor to block VEGF signaling, soluble receptor-
treated group had more collagen type II deposition in pellet culture (Mifune et al., 2013). 
Subcutaneous, intravenous, or intraarticular administration of anti-VEGF antibody Bevacizumab 
improved articular cartilage repair in rat and rabbit models (Nagai et al., 2010, 2014; Y. Wang, 
Da, Li, & Zheng, 2013). All these studies indicate that VEGF may impair the pro-chondrogenic 
potential of PRP. At the tissue level, VEGF signaling somehow induces degradation by producing 
MMPs; at the cellular level, VEGF and VEGF receptors lead stem cells or chondrocytes to 
hypertrophy. After all, cartilage is an avascular tissue. The balance between angiogenic factors and 
anti-angiogenic factors is crucial in this nature. 
VEGF, known as VEGFA, belongs to the superfamily that includes VEGFB, VEGFC, and 
VEGFD. VEGF, produced by pericytes, binds to two receptor tyrosine kinases VEGFR-1 (Flt-1) 
and VEGFR-2 (KDR or Flk-1) with different affinities (Ferrara, Gerber, & LeCouter, 2003). Once 
VEGF binds to the receptor, dimerization and auto-phosphorylation begins and leads to VEGF-
induced angiogenesis and vascularization (Murata, Yudoh, & Masuko, 2008; Stuttfeld & Ballmer-
Hofer, 2009). Known roles of VEGF include mitogenic signal transduction by activation of Ras-
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Raf-Mek-Erk pathway and activation of PI3K-Akt pathway for pro-survival signals (Ferrara et al., 
2003). Of particular relevance is that, in early embryonic development, VEGF is required for the 
endochondral ossification  (Carlevaro et al., 2000). This process is initiated by mesenchymal 
condensation, followed by chondrogenic differentiation to form a cartilage template (Carlevaro et 
al., 2000). Growth and maturation of the cartilage template in a structure known as the growth 
plate result in chondrocyte hypertrophy, accompanied by the upregulation of VEGF and 
subsequent vascularization (Carlevaro et al., 2000; Karimian et al., 2011). During this event, the 
hypertrophic chondrocytes undergo apoptosis, and are replaced by osteoblasts, ultimately resulting 
in bone formation (Carlevaro et al., 2000; Karimian et al., 2011). The critical key that leads 
chondrocytes to hypertrophy is still unclear, but VEGF is believed to play an important role. 
Therefore, we hypothesize that VEGF impairs IFP-ASC chondrogenesis, and that removal 
of VEGF from PRP can enhance IFP-ASC chondrogenesis. In this study, we utilized an 
experimental system of IFP-ASCs as high-density cell pellets in vitro. 
3.2 Methods 
3.2.1  Materials and Reagents 
All chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless 
indicated otherwise. 
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3.2.2  PRP Releasate Preparation  
Platelet-rich plasma (PRP) releasate was prepared according to an adapted protocol (J. 
Zhang & Wang, 2010).  Briefly, anticoagulated human whole blood (Central Blood Bank, 
Pittsburgh, PA) was distributed into 15 mL conical tubes (Thermo Fisher, Pittsburgh, PA) and 
centrifuged at 480 x g for 20 minutes at room temperature. Pelleted red blood cells were discarded; 
the middle layer buffy coat and the supernatant platelet-poor plasma was aspirated and 
concentrated to obtain a platelet concentration of 1x106 platelets/μL. To activate platelets, 22.8 
mM of calcium chloride (Sigma–Aldrich) was added and incubated at 37 oC overnight. After 
another centrifugation at 2000 x g for 10 minutes at room temperature, the fibrin clot was discarded 
and the supernatant, referred to as PRP releasate, was aliquoted and stored at -20 oC until future 
use. PRP releasate from six different donors were pooled in equal volume before each experiment. 
3.2.3  Cell Isolation and Preparation 
Human infrapatellar fat pad derived adipose stem cells (IFP-ASCs) were isolated from 
infrapatellar fat pads of three different donors undergoing total knee arthroplasty (48 years old 
female, 59 years old male, and 65 years old male) under an IRB-approved and exempted protocol 
(University of Pittsburgh and University of Washington). The tissue was digested with 1 mg/mL 
type I collagenase (Worthington Biochemical, Lakewood, NJ) and 1 mg/mL trypsin (Invitrogen, 
Carlsbad, CA) for 3 hours at 37C in an orbital shaker at 150 rpm. Cells were filtered through a 
40-micron cell strainer (Thermo Fisher), centrifuged at 1200 rpm for 5 minutes, and expanded in 
growth medium (DMEM, 10% v/v fetal bovine serum, and 1% v/v antibiotic-antimycotic). 
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Human bone marrow-derived mesenchymal stem cells (BM-MSCs) were isolated from the 
bone marrow of three different donors undergoing total knee or hip arthroplasty (65 years old male, 
67 years old male, and 68 years old male). The trabecular bone marrow was minced with surgical 
scissors and rinsed with Minimum Essential Medium Alpha (MEM; Invitrogen). Cells were 
filtered through a 40-m cell strainer (Thermo Fisher), pelleted by centrifugation at 1300 rpm for 
5 minutes, and expanded in growth medium. 
Human umbilical vascular endothelial cells (UVECs, #C2517A single donor) and UVEC 
culture medium (#CC-3162, each 500 mL endothelial growth medium-2 contains 0.5 mL of 
epidermal growth factor, 0.5 mL of vascular endothelial growth factor, 0.5 mL of R3-insulin-like 
growth factor, 0.5 mL of ascorbic acid, 0.2 mL of hydrocortisone, 2 mL of fibroblast growth factor 
2, 0.5 mL of heparin, 10 mL of fetal bovine serum, and 0.5 mL of gentamicin/amphotericin) were 
both purchased from Lonza (Basel, Switzerland). Cell culture medium was prepared according to 
manufacturer’s instructions.  
3.2.4  PRP Characterization 
The profiling of 41 growth factors and cytokines in PRP samples from six different donors 
(Demography can be found in supplementary table) was quantified by ELISA Microarray 
(RayBiotech #QAH-BMA-1000, Norcross, GA). Briefly, serial dilutions of cytokine standards and 
100 uL of samples were prepared. Sample diluent was added and incubated for 30 minutes prior 
to blocking for 1 hour. Biotinylated Antibody and Cy3 Equivalent Dye-Streptavidin were added 
separately for signal amplification. The sample slide was prepared and shipped to the manufacturer 
for subsequent analysis.  
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VEGF concentration was quantified using commercial enzyme-linked immunosorbent 
assay (ELISA) kits (R&D Systems #DVE00, Minneapolis, MN) according to manufacturer’s 
instructions.  
3.2.5  Cell Characterization 
The expression of cell surface markers including vascular endothelial growth factor 
receptors I, II, and III (VEGFR1, VEGFR2, VEGFR3), platelet-derived growth factor receptor 
beta (PDGFRβ) and transforming growth factor beta receptor II (TGFβR2) of IFP-ASCs, BM-
MSCs, and UVECs was assessed by flow cytometry.  
3.2.6  Monolayer Culture and Proliferation Assay 
To determine the metabolic activity, IFP-ASCs were plated on six-well plates as 
monolayers for up to 7 days in serum-free growth medium (DMEM and 2% ITS) and MTS Cell 
Proliferation Assay (Promega, Medison, WI) was performed at day 1, day 3, and day 7. At day 7, 
PicoGreen Assay (Invitrogen, Carlsbad, CA) was also performed to determine relative double-
stranded DNA level. Significant difference was determined when p<0.05. 
3.2.7  Pellet Culture and Differentiation Assay 
To mimic mesenchymal cell condensation in chondrogenesis during embryonic 
development, 2.5x105 IFP-ASCs were pelleted in serum-free chondrogenic medium (DMEM, 1% 
v/v antibiotic-antimycotic, 10 μg/mL insulin-transferrin-selenium, 0.1 μM dexamethasone, 40 
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μg/mL proline, 50 μg/mL ascorbic acid, and 10 ng/mL TGFβ3). Culture medium was changed 
three times a week. 
3.2.8  VEGF Knockdown  
IFP-ASCs were cultured as monolayers on tissue culture flasks. After 24 hours of plating, 
cells were washed with PBS and antibiotic-free transfection medium (DMEM with 10% FBS). 
IFP-ASCs were transfected with either 50 nM Human VEGF ON-TARGETplus SMARTpool 
siRNA (Dharmacon, Lafayette, CO) or 50 nM non-targeting control siRNA ON-
TARGETplus non-targeting siRNA #2 (Dharmacon, Lafayette, CO) using DharmaFECT1 
Transfection Reagent (Dharmacon, Lafayette, CO). DharmaFECT1 and each siRNA were 
prepared at 10× the final concentration used for transfection in antibiotic-free high glucose DMEM 
and incubated for 5 min at room temperature. Each siRNA was then mixed 1:1 with the 
DharmaFECT1 and incubated for 20 min at room temperature. Each siRNA/DharmaFECT mix 
was then diluted 1:5 in antibiotic-free growth medium and added to washed MSCs at 0.13 ml/cm2. 
The final volume of DharmaFECT used was 0.08 µl/cm2. After 24 hours of treatment, the medium 
was switched to regular growth medium (DMEM, 10% FBS, and 1% antibiotic-antimycotic). 
3.2.9  Mechanical Impacts 
Bovine articular cartilage explants were isolated from the patellofemoral groove of the 
hind-leg stifle of 2- to 3-year-old bovine within 24 hours of slaughter (JW Treuth and Sons, 
Baltimore, MD). In brief, 8-mm cartilage discs were removed from the subchondral bone in the 
articular surface with a steel biopsy punch and immediately place in basal medium (phenol red-
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free DMEM with 1% antibiotics). After 24 hours, a central 5-mm core was removed from the 8-
mm disc and cultured in serum-free chondrogenic medium (DMEM, 1% v/v antibiotic-
antimycotic, 10 μg/mL insulin-transferrin-selenium, 0.1 μM dexamethasone, 40 μg/mL proline, 
50 μg/mL ascorbic acid, and 10 ng/mL TGFβ3). After weighing, samples between 38 and 60 mg 
(approximately 1.8 to 2.2 mm in thickness) were randomly distributed into four different 
experimental groups for another 24 hours. On the day of the experiment, the cartilage samples 
were placed in the impact chamber (5 mm in diameter and 2.2 mm in depth), covered with a piece 
of polyvinyl-enclosed Pressurex Pressure Indicating Sensor Film, and subjected to 36 MPa of 
impact force. Impacted samples were returned to wells containing fresh chondrogenic medium and 
cultured for seven days. Medium was changed once at day 3. Four experimental groups: (1) 
Control, (2) Impacted, (3) PRP-treated, and (4) Impacted & PRP-treated. 
3.2.10  Western Blotting 
Western blotting was performed to confirm the antibody functions. Cells were seeded in 6-
well plates as monolayers and treated with 10 ng/mL of recombinant VEGF (rVEGF) and anti-
VEGF (treated with 500 ng/mL of anti-VEGF antibody) or IgG (treated with 500 ng/mL of IgG 
antibody) with no treatment as the control. Cells were trypsinized at 10, 20, 30 and 60 minutes. 
Total RNA was isolated for western blotting of VEGF and GAPDH to detect protein expression 
level of VEGF and GAPDH. 
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3.2.11  Gene Expression Analysis 
Pellet cultures were collected on day 21 and homogenized in Qiazol (Qiagen, Hilden, 
Germany). Total RNA was isolated with RNeasy Plus Mini Kit (Qiagen). Gene expression levels 
of chondrogenic markers (transcription factor SOX9, SOX9; collagen type II, COL2; aggrecan, 
ACAN), hypertrophic markers (collagen type X, COL10; matrix metalloproteinase 13, MMP13), 
osteogenic markets (collagen type I, COL1; runt-related transcription factor 2, RUNX2), and 
VEGF signaling pathway markers (vascular endothelial, growth factor, VEGF; VEGF receptor 1, 
FLT1; VEGF receptor 2 or kinase insert domain receptor 1, KDR1; neuropilin 1, NRP1; neuropilin 
2, NRP2) were assessed by real-time RT-PCR. All the gene expression levels were normalized to 
that of 18S ribosomal RNA (primer sequence shown in Supplementary Table). Relative fold 
changes were calculated using ΔΔCt method. 
3.2.12  Histological Analysis 
For histology, pellets were harvested on day 21, fixed with 4% paraformaldehyde, and 
embedded in paraffin. Eight-micron sections were stained with Safranin O/Fast Green for 
proteoglycans and Alcian Blue/Nuclear Fast Red for glycosaminoglycan. Immunohistochemical 
analysis was performed using anti-human collagen type II antibodies. Briefly, the slides were 
washed with 0.02% bovine serum albumin and incubated with 0.1 U/mL chondroitinase ABC 
(Sigma–Aldrich, St. Louis, MO) and 250 U/mL hyaluronidase (Sigma) for antigen retrieval. Three 
percent hydrogen peroxide (Company, Catalog) and 1% horse serum (Vector) was used for 
blocking. Samples were then incubated with rabbit anti-human collagen type II (Abcam, 
Cambridge, United Kingdom) at 4 °C overnight. Biotinylated anti-rabbit secondary antibody was 
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used to bind the primary antibody. Signals were amplified using ABC reagent (Vector, 
Burlingame, CA) and visualized with VIP Kit (Vector). Counterstain Hematoxylin QS (Vector) 
was used before mounting. 
3.2.13  Biochemical Analysis 
Papain (Sigma-Aldrich) was diluted in digestion buffer (0.1 M sodium acetate, 0.01 M 
cysteine HCl, 0.05 M EDTA, add ddH2O to 500 mL, adjust pH to 6.0) at 1:50. Pellets were digested 
with papain solution at 65C overnight. Sulfated GAG content was measured with the Blyscan 
GAG Assay (BioColor, Carrickfergus, United Kingdom) according to the manufacturer’s 
instructions. GAG content was normalized against DNA content determined with PicoGreen 
Assay (Invitrogen, San Diego, CA). 
3.2.14  Statistical Analysis 
Gene expression levels, GAG content, and DNA content are shown as mean  standard 
deviation. Three to six independent trials were performed for each experiment. One-way ANOVA 
and Tukey’s multiple comparisons test were performed using GraphPad Prism 7 (GraphPad 
Software Inc, CA) to determine the significant difference between groups. Significance was 
determined when p < 0.05. 
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3.3 Results 
3.3.1  Growth factor and cytokine profile of PRP 
To obtain the growth factor and cytokine profile of PRP, enzyme-linked immunosorbent 
assay (ELISA) microarray was performed. Forty-one growth factors and cytokines at the protein 
level were detected, including Activin A, aFGF, Amphiregulin, bFGF, E-Selectin, ICAM-1, IGF1, 
TNFa, IL1a, IL1b, IL6, IL8, IL11, IL17, MCP1, MCSF, MIP1a, MMP2, MMP3, MMP9, MMP13, 
Osteoactivin, P-Cadherin, VE-Cadherin, RANK, SDF-1a, Shh-N, TGFβ1, TGFβ2, TGFβ3, BMP2, 
BMP4, BMP6, BMP7, BMP9, Dkk-1, Osteoprotegrin, Osteopontin, PDGFBB, TRANCE, 
VCAM-1 (Figure 16A). A heat map was generated to facilitate comparison across donors (Figure 
16B). The demographic information of donors is listed in Appendix. 
EGF ELISA was performed and the concentration of EGF was quantified (Figure 17A). A 
variation across six different donors was observed and the concentration ranges between 0 and 
1,000 pg/mL. The concentration of VEGF was also quantified (Figure 17B). Concentrations 
averaged 150 pg/mL. This concentration is consistent with the concentration reported by Bertrand-
Duchesne et al. (Bertrand-Duchesne, Grenier, & Gagnon, 2010). In their study, the mean of 5 PRP 
donors was 189 + 7 pg/mL. 
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Figure 16. Growth factor and cytokine profile of PRP samples. 
(A) ELISA microarray of 41 growth factors and cytokines including proliferative growth factors (aFGF, 
bFGF), chondrogenic growth factors (TGFβ1, TGFbβ2, TGFbβ3, BMP2, BMP4, BMP6, BMP7, BMP9), catabolic 
factors (MMP2, MMP3, MMP9, MMP13), and pro-inflammatory cytokines (TNFa, IL1a, IL1b, IL6, IL8, IL11, 
IL17), endothelial markers (P-Cadherin, VE-Cadherin) (B) Heat map of 33 growth factors and cytokines that are 
20,000 pg/ml or below. 
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Figure 17. EGF and VEGF protein concentration in PRP samples.  
(A) ELISA of EGF shows that EGF concentration is averaged 500 pg/mL (n=3). one-way ANOVA, 
significant difference between different letters. (B) ELISA of VEGF (n=3). one-way ANOVA, significant difference 
between different letters. 
 
3.3.2  Effect of PRP on IFP-ASC proliferation 
Prior to differentiation assays, the effect of PRP on IFP-ASC proliferation was examined. 
MTS assays show that 10% (v/v) PRP significantly increased metabolic activity in IFP-ASC 
monolayer cultures at day 1, day 3, and day 7 (Figure 18A). At day 7, PicoGreen assay showed 
that 10% PRP significantly promoted IFP-ASC proliferation (Figure 18B).  
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Figure 18. Effect of PRP treatment on IFP-ASC metabolic activity and proliferation.  
(A) MTS assay shows 10% (v/v) PRP significantly promotes metabolic activity. (B) PicoGreen assay (cell 
number) shows 10% PRP significantly promotes cell proliferation. 
 
3.3.3  Effect of exogenous VEGF supplementation 
To examine the effect of VEGF on IFP-ASC chondrogenesis, IFP-ASCs were cultured in 
chondrogenic medium supplemented with PRP and 10 ng/ml recombinant VEGF (rVEGF) and 
analyzed at day 8. Exogenous rVEGF supplementation downregulated SOX9 and ACAN, while 
no significant difference was observed in the COL2 expression (Figure 19). However, when the 
rVEGF concentration was increased from 10 to 50 or 100 ng/mL, no significant difference was 
observed (data not shown). 
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Figure 19. Effect of exogenous VEGF supplementation on IFP-ASC pellet cultures.  
PRP pellets (chondrogenic medium supplemented with 10% v/v PRP) and PRP + rVEGF pellets 
(chondrogenic medium supplemented with 10% v/v PRP and additional 10 ng/mL recombinant VEGF) at day 8 
(n=5). 
 
3.3.4  VEGF receptor surface expression 
Next, we postulated that the lack of change of chondrogenesis observed as VEGF 
concentration was increased (i.e., increased ligand concentration) was partially due to the low 
expression of VEGF receptors on IFP-ASCs. To analyze the cell surface expression of VEGF 
receptors, IFP-ASCs were cultured as monolayers and then analyzed using flow cytometry. The 
results showed that IFP-ASCs expressed low level of VEGF receptor 1 (VEGFR1), VEGF receptor 
2 (VEGFR2), and VEGF receptor 3 (VEGFR3), but expressed high level of PDGF receptor beta 
(PDGFb). Expression of TGF beta receptor 2 was about 50% of that observed in BM-MSCs and 
human umbilical vein endothelial cells (UVECs) (Figure 20A). Quantitation of receptor surface 
expression was shown (Figure 20B). 
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Figure 20. Surface expression of monolayer cultured IFP-ASCs, BM-MSCs, and UVECs.  
(A) Characteristics of IFP-ASCs is indicated by high expression of PDGF receptor beta and TGF beta 
receptor 2 (50% parent) with negligible expression of VEGF receptor 1, VEGF receptor 2, and VEGF receptor 3 
(n=3). (B) Quantification of surface expression in IFP-ASC, BM-MSC, and UVEC monolayer cultures. 
 
3.3.5  Effect of anti-VEGF treatment  
To manipulate VEGF level, in addition to VEGF supplementation, VEGF was also 
depleted from PRP by immunoadsorption using anti-VEGF antibody. VEGF antibody was 
supplemented to chondrogenic medium. [Note: 1 ug/ml was most common concentration of this 
antibody used in other similar studies (Allerstorfer et al., 2008; Hatfield, Ryningen, Corbascio, & 
Bruserud, 2006).] Our results showed that at day 7, SOX9 expression remained the same; ACAN 
expression decreased in PRP group but anti-VEGF antibody rescued this reduction (data not 
shown). At day 21, treatment with anti-VEGF antibodies significantly improved SOX9, COL2, 
and ACAN expression when compared to the PRP-treated group in high-density pellet cultures 
(Figure 21A). This finding was consistent with changes in the measured value of sulfated GAG 
content per pellet (Figure 21B). 
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Figure 21. Effect of anti-VEGF treatment on IFP-ASC pellet culture. 
(A) Anti-VEGF treatment can recover PRP-induced loss of SOX9, COL2, and ACAN gene expression in 
IFP-ASC pellet cultures. (B) Anti-VEGF treatment increases sulfated GAG deposition when compared to the PRP 
group. (C) Safranin O staining of IFP-ASC pellet cultures confirms the beneficial effect of anti-VEGF treatment on 
IFP-ASC chondrogenic differentiation. 
 
3.3.6  Anti-inflammatory effect of PRP 
The anti-inflammatory effect of PRP was also evaluated. The response of IFP-ASC to pro-
inflammatory cytokines, IL1 and IL6, was examined in 21-day pellet cultures. The results showed 
that IL1 significantly decreased sulfated glycosaminoglycan deposition in IFP-ASC pellets at 14 
days; no significant effect was observed in the IL6-treated group when compared to the control 
(Figure 22). We also tested the effect of IL1 in hydrogel cultures. Results show that IL1 
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significantly downregulated collagen type II (COL2) and aggrecan (ACAN) expression on day 7 
while upregulating matrix metalloproteinase 3 (MMP3) at day 1 (Figure 23). 
To examine the anti-inflammatory effect of PRP on injured cartilage, bovine cartilage plugs 
were impact-injured using an impactor custom-designed by our laboratory and then treated with 
PRP at 10% (v/v) for up to 7 days. No significant difference was detected between Impacted and 
Impacted & PRP-Treated groups at the gene expression level of MMP1, MMP3, MMP13, 
ADAMTS4, ADAMTS5, COX2, iNOS, RUNX2, IHH, SMO, or PTCH (data not shown). 
Quantitation of the anti-inflammatory cytokines IL4 and IL10 in six PRP samples using ELISA 
assays showed that the IL4 concentration in all samples was lower than the detection limit at 1 
pg/mL (data not shown).   
 
 
Figure 22. Effect of IL6 and IL1 on IFP-ASC pellet cultures.  
IL1 significantly decreased GAG/DNA of IFP-ASC pellets at day 7 and day 14. *, p < 0.05. 
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Figure 23. Effect of IL1 on three-dimensional hydrogel cultures.  
IL1 significantly downregulates COL2 and ACAN at day 7 while at day 1, MMP3 is highly upregulated 
in IL1 treated group. *, p < 0.05. 
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3.4 Discussion 
This study provides a perspective of how VEGF, as a component of PRP, can impair IFP-
ASC chondrogenic differentiation, and shows that blockage of VEGF can improve 
chondrogenesis. Exogenous VEGF at 10 ng/mL downregulated chondrogenic gene expression. 
Lozito et al. also reported no difference between VEGF treatments on BM-MSCs in the absence 
or presence of 5, 25, or 50 ng/mL of VEGF (Lozito, Kuo, Taboas, & Tuan, 2009). It is possible 
that this is related to the fact that VEGF receptor expression level in MSCs is low, e.g., less than 
in endothelial cells (e.g., human umbilical vein endothelial cells). Indeed, our data show that VEGF 
receptors are barely found on the surface of IFP-ASCs. ASCs derived from subcutaneous tissues 
had similar surface expression profile – a low expression of VEGF receptors but high expression 
of PDGF receptor beta (Hutton et al., 2012; Shevchenko et al., 2013). 
Among the growth factors that are released from platelets after platelet activation, VEGF 
is essential for mitogenic and pro-survival signals (Ferrara et al., 2003). In early embryonic 
development, VEGF is required for the endochondral ossification process of skeletogenesis 
(Carlevaro et al., 2000). This process is initiated by mesenchymal condensation, followed by 
mesenchymal chondrogenic differentiation to form a cartilage template (Carlevaro et al., 2000). 
Growth and maturation of the cartilage template in the growth plate result in chondrocyte 
hypertrophy, accompanied by the upregulation of VEGF and subsequent vascularization 
(Carlevaro et al., 2000; Karimian et al., 2011). During this event, the hypertrophic chondrocytes 
undergo apoptosis and are replaced by osteoblasts, ultimately resulting in bone formation 
(Carlevaro et al., 2000; Karimian et al., 2011). The critical key that leads to hypertrophy is still 
unclear, but VEGF is believed to play an important role. Studies have shown hypoxia-inducible 
factor 1-alpha (HIF1) leads to transcriptional activation of the VEGF gene in hypoxic cells. In 
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the growth plate, reduced oxygen level induces HIF1 expression which induces VEGF 
transcriptional activation (Murata et al., 2008), and that HIF1 and VEGF act coordinately to 
maintain cartilage metabolism under hypoxic conditions (Nagao et al., 2017). HIF1 also acts 
through VEGF-independent mechanisms because overexpression of VEGF in HIF1-deficient 
mice only partially rescues the aberrant hypoxia phenotype (Macs 2012 J Bone Miner Res; Pfander 
2003 J Cell Sci; Schipani 2001 Genes Dev). In chondrocytes, HIF1 increases the expression of 
VEGF and promotes angiogenesis in the surrounding perichondrium (Wang 2007 J Clin Invest; 
Riddle 2009 J Mol Med). Overexpression of the HIF1 target, VEGF, in chondrocytes also results 
in excessive endochondral bone formation (Macs 2010). 
At the cellular level, VEGF controls mitogenic and pro-survival signals through multiple 
signaling pathways. VEGF, known as VEGFA, belongs to the superfamily that includes VEGFB, 
VEGFC, and VEGFD. VEGF can bind to two receptor tyrosine kinases VEGFR-1 and VEGFR-2 
with different affinities (Ferrara et al., 2003). Once it binds to the receptor, dimerization and auto-
phosphorylation begins and turns on downstream signaling cascades (Stuttfeld & Ballmer-Hofer, 
2009). Most of the proliferation and survival signals come from VEGFR2 (Ferrara et al., 2003), 
so we hypothesize VEGF actions on chondrogenesis via VEGFR2 signaling.  
VEGFR2 signaling can be inhibited via ligand sequestration (e.g., monoclonal antibody or 
soluble receptor that directly binds to ligand) or receptor blocking (e.g., small molecule inhibitor 
that binds to ATP pocket and prevents receptor phosphorylation). Among all small inhibitors, 
VEGF receptor 2 inhibitor SU1498 has been investigated. SU1498 prevents tyrosine kinase 
phosphorylation, and it inhibits VEGF-induced histone deacetylase stabilization and Akt 
phosphorylation in embryonic stem cells (Zeng et al., 2006). SU1498 also blocked shear stress-
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induced VEGFR2-positive embryonic stem cells differentiating towards endothelial cells, while a 
VEGF neutralizing antibody did not (Yamamoto et al., 2005).  
Gene silencing can also knockdown VEGF signaling. VEGF siRNA has been widely used 
in cancer research (S. H. Kim, Jeong, Lee, Kim, & Park, 2008), but only in a few studies in the 
orthopedic field. Among them, most of the gene silencing strategies targeted HIF1, an upstream 
molecule of VEGF signaling (Kakudo, Morimoto, Ogawa, Taketani, & Kusumoto, 2015; L. Lin 
et al., 2011; C. Zhang, Li, Cornelia, Swisher, & Kim, 2012). However, Prasadam et al. treated 
human umbilical vein endothelial cell (HUVEC)/osteocyte cocultures with VEGF siRNA and 
found that proliferation, cell migration, tubule formation, or angiogenic gene expression of 
HUVECs was significantly reduced (Prasadam et al., 2014). Conditional deletion of VEGF in 
chondrocytes caused massive cell death in growth plate chondrocytes and reduced angiogenesis in 
the primary ossification center (Zelzer et al., 2004).  
Gerber et al. inactivated VEGF systemically in mice and found that inhibition of VEGF 
activity impaired bone formation and expanded hypertrophic chondrocytes with almost complete 
suppression of blood supply (Gerber et al., 1999). Zelzer et al. generated VEGF knockout mice 
and found impaired embryonic bone development (Zelzer et al., 2004). 
The result from our study is in line with several studies. VEGF-transduced muscle-derived 
stem cells performed poorly in chondrogenesis in a rat model and reported a catabolic role of 
VEGF on matrix degeneration (Kubo et al., 2009b; Matsumoto et al., 2009). When combined with 
the soluble receptor to block VEGF signaling, the soluble receptor-treated group had more 
collagen type II deposition in pellet culture (Mifune et al., 2013). When treated with anti-VEGF 
antibody intravenously, antibody treatment improved articular cartilage repair in a rabbit model 
(Nagai et al., 2010). Nagao et al. demonstrated that conditional knock-down of VEGF attenuates 
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induced OA and intra-articular anti-VEGF antibodies suppress OA progression in a mouse model 
(Nagao et al., 2017). A summary of relevant VEGF studies has been summarized in Table 1. 
It has been hypothesized that Bevacizumab can function like chondomodulin-1 as an anti-
angiogenic factor in maintaining the avascular nature of cartilage tissue (S. Lee, Nemeño, & Lee, 
2016). The limitation of this study is that the effect of VEGF was only evaluated in vitro. 
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Table 1. Effect of VEGF on chondrogenic differentiation for cartialge repair. 
Condition Treatment Outcome Reference 
Mono-iodoacetate 
induced arthritis 
by one IA 
injection in rats 
Gene 
transduction, IA 
injection 
VEGF-transduced muscle-derived stem 
cells performed poorly in 
chondrogenesis in a rat model and 
reported a catabolic role of VEGF on 
matrix degeneration. 
 
(Matsumoto 
et al., 2009) 
Osteochondral 
defect model (1.8 
mm diameter 2.0 
mm depth) in rats 
Gene 
transduction, IA 
injection 
VEGF-transduced muscle-derived stem 
cells performed poorly in 
chondrogenesis in a rat model and 
reported a catabolic role of VEGF on 
matrix degeneration. 
 
(Kubo et al., 
2009a) 
Osteochondral 
defect (5 mm 
diameter 3 mm 
depth) in rabbits 
Bevacizumab IV Intravenous administration of anti-
VEGF antibody improved articular 
cartilage repair compared to defect the 
only group at one month and three 
months in a rabbit model. 
 
(Nagai et al., 
2010) 
No injury in mice Bevacizumab 
Hyaluronic 
acid/fibrin 
subcutaneous 
implants 
Incorporation of anti-VEGF antibody 
inhibited host vessel ingrowth but 
enhanced construct survival rate at 
three and six weeks. Subcutaneous 
implantation of nasal chondrocytes-
encapsulated fibrin/hyaluronan 
scaffold and incorporation of 
Bevacizumab does not affect cartilage 
matrix deposition in a nude mouse 
model. 
 
(Centola et 
al., 2013) 
Monosodium 
iodoacetate 
induced arthritis 
by one IA 
injection in rats 
Gene 
transduction 
with/without 
PRP, IA 
injection 
When combined with the soluble 
receptor to block VEGF signaling, the 
soluble receptor-treated group had 
more collagen type II deposition in 
pellet culture. 
 
(Mifune et 
al., 2013) 
Anterior cruciate 
ligament 
transection in 
rabbits 
Bevacizumab IV 
and IA 
IV injections reduced cartilage 
degeneration and osteophyte 
formation; IA injections are better than 
IV injections. 
 
(Nagai et al., 
2014) 
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Table 1 (continued) 
No injury in nude 
mice 
Gene transduction, 
subcutaneous 
implantation 
VEGF blockage by retroviral 
transduction of sFlk1 does not 
affect chondrogenic differentiation 
of nasal chondrocytes in vitro, but 
the implantation of chondrocyte-
encapsulated collagen scaffold 
increases glycosaminoglycan 
deposition in a nude mouse model. 
 
(Medeiros 
Da Cunha 
et al., 
2017) 
Surgical induced 
OA by 
destabilization of 
medial meniscus 
in mice 
Conditional 
knockdown of VEGF, 
intra-articular injection 
of anti-VEGF 
antibodies, and oral 
administration of 
VEGFR2 kinase 
inhibitors 
(Vandetanib) 
Conditional knock-down of VEGF 
attenuates induced OA. Intra-
articular anti-VEGF antibodies 
suppress OA progression, reduce 
levels of phosphorylated VEGF 
receptors. Finally, oral 
administration of the VEGFR2 
kinase inhibitor attenuates OA 
progression. 
 
(Nagao et 
al., 2017) 
Note: IA: intra-articular; IV: intra-venous; OA: osteoarthritis; VEGF: vascular endothelial growth 
factor. 
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3.5 Conclusion 
Exogenous VEGF supplementation decreased chondrogenic gene expression in IFP-ASC 
pellet cultures. PRP treatment decreased chondrogenic gene expression when compared to 
TGF3+/PRP- controls. Anti-VEGF antibodies rescued PRP-induced loss of chondrogenesis. 
These results showed that VEGF, as one component in PRP, acts to impair MSC chondrogenesis 
in vitro. Understanding the involvement of VEGF in PRP on MSC chondrogenesis is necessary to 
optimize the application of PRP in combination with cell-based therapy for the repair of focal 
cartilage defects. For example, autologous MSCs encapsulated mixed with VEGF-depleted PRP 
in hydrogel may be injected into the defect site, resulting in optimal MSC chondrogenic 
differentiation and production of cartilage extracellular matrix, and the formation of functional 
neo-cartilage. 
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4.0 Discussion 
Current clinical treatments for cartilage injuries mostly only target short-term pain and 
provide temporary restoration of joint function. Surgical procedures, in addition to being 
destructive in nature, are also associated with risks of infection, inflammation, post-surgery failure, 
and need for surgical revision. We have reviewed here the principles and progress of current tissue 
engineering approaches that have the potential to repair or regenerate skeletal soft tissues, 
specifically cartilage. Critical to the success of a regenerative medicine approach is the 
development of a biomaterial scaffold that, with the appropriate delivery of requisite growth and 
inductive factors, can provide cells with the optimal environment and niche to grow and 
differentiate, and to regenerate a neo-tissue that is able to mature and remodel in concert with and 
in response to the physiology of the native tissue milieu (Figure 24). 
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Figure 24. Tissue engineering approach for osteochondral defect repair. 
Ultimately, an autologous cell-based therapy is an osteochondral implant that contains cells, bioactive 
factors, and scaffolds. There are four different zones (superficial zone, middle zone, deep zone, and calcified zone). 
 
Several native and synthetic scaffolds are under investigation for tissue regenerative 
applications. Native biopolymeric scaffolds have natural extracellular matrix microstructure, 
which promotes cell adhesion, migration, infiltration, proliferation, and differentiation. However, 
poor mechanical properties and nonspecific and unregulated inductive activities are the limitations 
of current biological scaffolds. Synthetic, or polymeric, scaffolds have defined mechanical 
properties with quality consistency, but are not as biocompatible as native matrix-derived 
scaffolds. Future development in scaffold technology thus needs to be grounded in the natural 
history of soft tissue development and biology. 
In terms of bioactive factors, the use of PRP remains controversial. Although PRP is a 
natural product, may be obtained autologously and rapidly implemented, and requires no or little 
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regulatory clearance, more investigations, particularly controlled clinical trials, are clearly needed 
to yield conclusive evidence to indicate its value for cartilage regeneration and what the standard 
procedure should be. In comparison, the bioactive factor, TGFβ, while having shown efficacy in 
improving tissue differentiation and regeneration in cell culture and animal models, does not have 
FDA approval for clinical use.  
The most promising cell type for skeletal soft tissue engineering and regeneration is the 
MSC, derived from bone marrow or other tissues, such as adipose.  MSCs that have undergone 
minimal or no culture expansion are preferred as they possess more robust proliferative and 
differentiation potential.  MSCs are optimally delivered in 3D scaffolds that are formed in a manner 
that allows optimal cell capsulation, and recent developments in 3D bioprinting present interesting 
options in scaffold design and fabrication.  The potential of using allogeneic MSCs should also be 
explored, particularly given the extensive literature supporting the low, intrinsic immunogenicity 
of MSCs. 
In conclusion, contemporary advances in stem cell biology, developmental biology, and 
scaffold technologies have provided exciting possibilities in developing regenerative therapeutic 
approaches for the repair of injuries to cartilage.  The potential of functional restoration will 
significantly alleviate the disease burden of these debilitating injuries and improve the quality of 
life of a significant segment of society.  Sustaining the breakthroughs through the continuous 
convergence of life science and engineering is critical to reach these goals. 
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4.1 Summary 
The central hypothesis of this dissertation is that PRP modulates IFP-ASC chondrogenesis 
and that removal of VEGF enhances IFP-ASC chondrogenesis for cartilage tissue engineering. In 
Aim 1, the effect of PRP on IFP-ASC chondrogenesis was examined in high-density pellet cultures 
and three-dimensional hydrogel cultures. Results show that treatment with high concentration PRP 
for extensive time periods impairs IFP-ASC chondrogenesis in both pellet and hydrogel cultures. 
In Aim 2, the effect of VEGF as a bioactive component of PRP was examined. Results show that 
exogenous VEGF supplementation downregulates chondrogenic gene expression and treatment of 
anti-VEGF antibodies was able to rescue PRP-induced loss of chondrogenesis. In Aim 3, PRP in 
combination with ASCs in hydrogel was examined in a rabbit study for osteochondral defect 
repair. 
As mentioned above, the complexity of PRP research is due to the variability between 
donors, and how PRP is processed and delivered (Table 2). In this dissertation, one growth factor 
– VEGF – was identified as the chondro-inhibitory factor, providing information on future 
application for cartilage tissue engineering. 
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Table 2. Variables of PRP treatments for cartilage repair 
Variable Sub-Variable 
Donor 
Age (Andia & Maffulli, 2013; Elizaveta Kon et al., 2011), gender, 
comorbidities, concurrent medications (anti-inflammatory drugs), nutritional 
status, activity level  (J. S. Wang et al., 1994) 
Processing 
Blood collection and storage conditions, spin protocol (speed, time) (Amable et 
al., 2013), activation protocol (agent, concentration, timing) (Amable et al., 
2013) 
Delivery 
Form of delivery (gel, solution) (Dohan Ehrenfest et al., 2009), timing of 
delivery in relation to isolation or activation, injury chronicity, dosing regimen 
(single, repeat) 
Adapted from reference (LaPrade et al., 2016) 
4.2 Future Perspectives 
4.2.1  Rabbit Model 
The following information will be submitted as a manuscript - Liou, J. J., Iseki, T., 
Rothrauff, B. B., Kihara, S., Alexander, P. G., & Tuan, R. S. (in preparation) Application of 
platelet-rich plasma in combination with adipose stem cells encapsulated in three-dimensional 
hydrogel in a rabbit model of cartilage repair.  
Rabbit subcutaneous adipose tissue was harvested from the dorsomedial line of six post-
breeder New Zealand white rabbits (6-month-old female, average 4.0 kg, average 30 g of tissues 
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per rabbit) under an IACUC-approved and –exempted protocol (University of Pittsburgh). The 
adipose tissue was accessed through a longitudinal incision in the dorsomedial line (couple 
centimeters from the skull in the craniocaudal direction) (Figure 25). The adipose tissue was 
digested with 2 mg/mL Type I collagenase (Worthington Biochemical, Lakewood, NJ), 1 mg/mL 
trypsin (Invitrogen, Carlsbad, CA), and 2% antibiotic-antimycotic (Invitrogen) in Dulbecco’s 
Modified Eagle’s Medium (DMEM; Invitrogen) at 2 mL per gram of tissue at 37 oC for 3 hours. 
After enzyme digestion, rabbit ASCs were filtered, centrifuged at 1,200 rpm for 5 minutes, and 
expanded in growth medium (DMEM, 10% fetal bovine serum [Gemini Bio Products, West 
Sacramento, CA], and 1% antibiotic-antimycotic). The demographic profile of rabbit donors is 
listed in Appendix. 
 
 
Figure 25. Isolation of rabbit addipose tissue. 
(A) Donor rabbits were euthanized, and hair was shaved using a razor. (B) After a 10 cm incision, H-shape 
fat tissue was exposed. (C) Rabbit adipose tissue was harvested from the dorsomedial line of the donor rabbit and 
collected in 50 mL conical tubes prior to enzyme digestion (n = 6 rabbits). 
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Tri-lineage differentiation of rabbit ASCs was analyzed via monolayer culture in: (1) 
chondrogenic medium (DMEM, 1% v/v antibiotic-antimycotic, 10 μg/mL insulin-transferrin-
selenium (ITS; Invitrogen, Carlsbad, CA), 0.1 μM dexamethasone, 40 μg/mL proline, 50 μg/mL 
ascorbic acid, and 10 ng/mL recombinant human transforming growth factor-β3 [PeproTech #100-
36E, Rocky Hill, NJ]); (2) osteogenic medium (DMEM, 10% v/v FBS, 1% v/v antibiotic-
antimycotic, 0.1 μM dexamethasone, 10 mM β-glycerophosphate, and 50 μg/mL ascorbic acid); 
and (3) adipogenic medium (DMEM, 10% v/v FBS, 1% v/v antibiotic-antimycotic, 1 μg/mL ITS, 
1 μM dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine (IBMX)).  On day 21, the cultures 
were stained with Alcian Blue, Alizarin Red, and Oil Red O, using standard histological staining 
protocols, to assess chondrogenesis, osteogenesis, and adipogenesis, respectively. 
Briefly, 15 grams of gelatin (Sigma-Aldrich) was dissolved in 500 mL H2O at 37°C, and 
15 mL of methacrylic anhydride (Sigma-Aldrich) was added dropwise (H. Lin, Cheng, et al., 
2014). The mixture was incubated with shaking at 150 rpm for 24 hours, then dialyzed against 
water for four days, and methacrylated gelatin lyophilized for storage. The photoinitiator, lithium 
phenyl-2,4,6-trimethylbenzoylphosphinate (LAP), was prepared as described by Fairbanks et al. 
For methacrylated hyaluronic acid, 5 gram of sodium hyaluronate (66kDa, Lifecore Biomedical, 
Chaska, MN) was dissolved in 500 mL H2O at 37°C, and 15 mL of methacrylic anhydride (Sigma-
Aldrich) was added dropwise. At the end of every hour in the first 5 hours, pH was adjusted to 7.  
The mixture was then incubated with shaking at 150 rpm for 24 hours, dialyzed against water for 
four days, and lyophilized for storage. To fabricate hydrogels, methacrylated gelatin and 
methacrylated hyaluronic acid were dissolved in Hank’s Balanced Salt Solution (HBSS) with final 
concentration at 9% and 1% (w/v), respectively. pH was adjusted to 7.4 with 10 N NaOH and 1% 
antibiotic-antimycotic and 0.15% w/v LAP were added.   
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Nine ml of blood from each New Zealand White Rabbit was drawn and collected into 1 ml 
of filter sterilized 3.8% Na-citrate (3.8 g in 100 ml ddH2O) pre-loaded into the collection syringe. 
A 50 µl aliquot was removed from the syringe to obtain the platelet concentration, total white 
blood cell count, and neutrophil cell count. The rest of the syringe was immediately transferred to 
a 15 ml conical tube and centrifuged for 10 min at 200 x g. The clear layer (approximately 3 ml) 
was removed from the red blood cell pellet being careful not to remove any of the leukocyte-rich 
white interface. The clear layer was spun again for 10 min at 1000 x g. The supernatant was 
carefully removed leaving lower 500 µl and the pellet undisturbed. The supernatant was placed in 
a separate 15 ml conical as platelet-poor plasma (PPP), from which a platelet count was obtained. 
The pellet in the remaining 500 µl was resuspended and considered the platelet-rich plasma (PRP). 
Platelets were counted in both fractions and the whole blood after red blood cell lysis using a 
standard hemocytometer and an inverted microscope with 40X objective. At this point, the 
autologous PRP was ready for use. Detailed information of each rabbit PRP was listed in 
Appendix. One mL of whole blood or PRP was collected and sent to Marshfield Labs (Marshfield 
Labs, Marshfield, WI) for complete blood count (CBC) with automated differential within 24 
hours at ambient temperature. CBC data included platelet number, white blood cell number, and 
the percentage of neutrophils, lymphocytes, monocytes, eosinophils, and basophils. 
Another one mL of PRP was aliquoted and frozen for ELISA microarray. A 41-growth 
factor and cytokine profile were quantified using ELISA Microarray (RayBiotech #QAH-BMA-
1000, Norcross, GA). Briefly, serial dilutions of cytokine standards and 100 µL of samples were 
prepared. Sample diluent was added and incubated for 30 minutes prior to blocking for 1 hour. 
Biotinylated Antibody and Cy3 Equivalent Dye-Streptavidin were added separately for signal 
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amplification. The sample slide was prepared and shipped to the manufacturer for subsequent 
analysis. Each sample for each protein was four replicates. 
Thirty mature New Zealand white rabbits (9-month-old, averaged 4 kg, 15 male and 15 
female) were divided into six experimental groups: (1) sham (sham control), joint capsule was cut 
open and closed; (2) defect (defect only control), defect was left without treatment and closed; (3) 
hydrogel (scaffold only control), defect was filled with 10% methacrylated gelatin/1% 
methacrylated hyaluronic acid/0.15% photoinitiator (hereinafter GelMA); (4) hydrogel + ASC, 
defect was filled with cell suspension at 20 x 106 cells/ml in 10% GelMA; (5) hydrogel + PRP, 
defect was filled with PRP in 10% GelMA; and (6) hydrogel + ASC + PRP, defect was filled with 
cell suspension at 20 x 106 cells/ml and PRP in GelMA.  
Each group had five rabbits, and each rabbit was operated bilaterally (n=10 knees per 
group). Briefly, the knee joints were opened via a medial parapatellar incision, and the patella was 
reflected laterally to expose the femoral articular surface of the joint. A critical-sized defect of 5 
mm in diameter and 5 mm in depth was created on the trochlear groove. To differentiate the donor 
cells from host cells, ASCs were pre-treated with CellTracker CM-DiI Dye (Thermo Fisher, 
Pittsburgh, PA) at 37 °C for 5 minutes and cooled on ice for 15 minutes before cell implantation. 
For ASC-containing groups, ASC pellets were then resuspended in GelMA solution at a final 
concentration of 20 x 106 cells/mL, and the suspension transferred to a 1.5 mL tube, and 100 uL 
was injected to the defect. The cell/monomer mixture was subjected to photoillumination (395 nm) 
for 5 minutes, forming a cell-laden GelMA hydrogel. For PRP-containing groups, autologous PRP 
was mixed with allogenic ASC suspension prior to injection to the defect sites. The demographic 
information of 30 rabbits can be found in Appendix. 
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In this study, ASCs obtained from rabbit subcutaneous tissues were used in allogeneic cell 
transplantation. Rabbit ASCs from all six donor rabbits were able to differentiate into adipogenic, 
osteogenic, and chondrogenic lineages (Figure 26).  Pellet cultures consisting of 2.5 x 105 ASCs 
were maintained in chondrogenic medium for 3 weeks.  
 
 
Figure 26. Tri-lineage differentiation of rabbit ASCs. 
Rabbit ASCs were cultured in chondrogenic, osteogenic, or adipogenic medium for 21 days and stained 
with Alcian Blue, Alizarin Red, and Oil Red O, respectively. 
 
Thirty New Zealand white rabbits were divided into 6 treatment groups: defect only 
(negative control), hydrogel only, hydrogel+cells, hydrogel+PRP, hydrogel+cells+PRP, and sham 
(positive control). An incision was made from the lateral side of the articular joint. The joint 
capsule was open and trochlear groove was exposed (Figure 27A). For all groups except Sham, 
an osteochondral defect with 5 mm in diameter and 5 mm in depth was created on the trochlear 
groove using sterilized drill bits (Figure 27B). For hydrogel groups, 0.1 mL of photocrosslinkable 
hydrogel solution (or cell-containing hydrogel solution) was injected to the defect and photo-
polymerized for 5 minutes (Figure 27C). The joint capsule and the skin layers were closed. 
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Figure 27. Cell implantation in rabbit osteochondral defects.  
(A) An incision was made from lateral side and joint capsule was open to expose the trochlear groove. (B) An 
osteochondral defect (5 mm diameter, 5 mm depth) was created on the trochlear groove. (C) Photocrosslinkable 
hydrogel solution (0.1 mL) was injected to the defect and photo-polymerized for five minutes before wound closure. 
 
An application of VEGF-depleted PRP is presented and compared to the outcomes of 
whole PRP, cell only control, hydrogel only control, defect (negative control), and sham (positive 
control). The novelty of this study is: (1) to the best of our knowledge, the application of VEGF-
depleted PRP has not been examined in a translational context; (2) most of the osteochondral defect 
repair studies do not report the outcomes of sham or positive control, which would be more 
informative of how PRP treatment benefits osteochondral defect repair; and (3) lastly, almost all 
published studies do not report the mechanical properties of neo-tissue. As mentioned earlier, the 
mechanical strength is the critical factor to the restoration of cartilage function. 
Previously, a study of BMSCs and ADSCs seeded within PRP scaffold in a rabbit model 
with an osteochondral defect of 4 mm diameter and 3 mm depth was analyzed at nine weeks (Xie 
et al., 2012). This study compared the four different groups of unfilled (untreated group), PRP, 
PRP-ADSC, and PRP-BMSC, with 9 rabbits (18 defects) each and found that PRP-BMSC group 
significantly improved cartilage repair (Xie et al., 2012). However, cell only group was not 
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included; therefore, it was difficult to conclude whether the PRP or cells contributed to the 
improvement of cartilage repair. 
Lee et al. tested the effects of rabbit synovial membrane-derived mesenchymal stem cells 
and rabbit PRP on osteochondral defect (4 mm diameter 3 mm depth) repair in 81 rabbits (J.-C. C. 
Lee et al., 2013). In the first four weeks, PRP-SDSC group showed significant improvement on 
defect repair; however, the repair level was very similar between the groups with and without stem 
cells at 12 weeks and 24 weeks (J.-C. C. Lee et al., 2013).  
A comparison of rabbit PRP and saline (placebo) was performed in an osteochondral defect 
model (3 mm diameter 5 mm depth) in 12 rabbits at 3, 6, and 12 weeks. ICRS histological score 
was significantly better in PRP group (Smyth et al., 2016). However, no biochemical or 
mechanical analysis was performed, and the sample size might be too small to reach significant 
difference (Smyth et al., 2016).  
Liu et al. reported that the use of a photo-crosslinkable PRP hydrogel, compared to non-
crosslinkable PRP hydrogel and defect only groups, significantly improved cartilage repair at 12 
weeks in a rabbit model (Xiaolin Liu et al., 2017). Unfortunately, manipulation of autologous PRP 
is not yet allowed in the operating room and to commercialize this photo-crosslinkable PRP 
hydrogel is challenging. 
Several studies compared PRP treatment (usually in cell-containing scaffolds) to defect only 
group. These comparisons make the data interpretation complicated due to the following reasons: 
(i) PRP acts as an adjunct that provides growth factors and anti-inflammatory mediators. Rather 
than making extracellular matrix itself, the cells derived either from cell implantation or 
subchondral bleeding could contribute to the production of cartilage extracellular matrix, including 
collagen and aggrecan. (ii) The defect size is smaller than the critical size in most of the studies. 
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The critical size of a cartilage defect in rabbits is 5 mm in diameter (Ahern, Parvizi, Boston, & 
Schaer, 2009; Chu, Szczodry, & Bruno, 2010; Xiaohua Liu, Jin, & Ma, 2011). Smaller diameters 
may lead to endogenous healing and misinterpretation of treatment outcomes. It is difficult to 
differentiate between the contribution of endogenous healing versus cell-based therapy (Ahern et 
al., 2009; Chu et al., 2010; Xiaohua Liu et al., 2011). In fact, studies have shown that for chondral 
or osteochondral defect smaller than the critical size, the defect heals naturally. (iii) PRP 
preparation protocol and composition are not reported in detail.  Dohan Ehrenfest et al. 
summarized current protocols for pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin (PRF), 
and leukocyte-rich PRF based on the speed and time of centrifugation and portion collected after 
centrifugation (Dohan Ehrenfest et al., 2009). Lack of information on whether it is PRP or PRF 
would make it challenging to compare between studies; we, therefore, summarize several relevant 
rabbit PRP studies for comparison (Table 3). 
One of the limitations of our study is that the TGFß3 release profile of hydrogel in all 
groups was not evaluated in vitro. Prior to cell implantation, 2 ug/mL of TGFß3 was added to the 
hydrogel solution. This concentration is two hundred times higher than the standard concentration 
of 10 ng/mL for in vitro experiments.  
Recently, leukocytes were reported to be an inhibitory factor in PRP, acting to suppress 
chondrogenesis and cartilage report (Xu et al., 2017). A research study compared PRP with 
leukocyte-reduced PRP and concluded that leukocytes in PRP downregulated the synthesis of 
collagen types I and III (González, López, Álvarez, Pérez, & Carmona, 2016). PRP also inhibited 
the mechanically induced catabolic and inflammatory responses in chondrocytes in vitro, with 
early addition of PRP showing the most significant benefits. The effect of leukocyte on cartilage 
repair was not compared in our study. Another limitation is that the PRP used in our study is the 
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liquid form of platelet-rich plasma. Several studies have suggested that platelet-rich fibrin, known 
as PRF, has better healing potential when compared to liquid-like platelet-rich plasma (Maruyama 
et al., 2017).  
In conclusion, the application of VEGF-depleted PRP is presented and compared to the 
outcomes of whole PRP, cell only control, hydrogel only control, defect (negative control), and 
sham (positive control) in our study. We provided the information on the potential application of 
VEGF-depleted PRP for cartilage repair. 
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Table 3. Relevant PRP rabbit studies 
Condition Intervention PRP Specifics Outcome Reference 
4 mm 
diameter 3 
mm depth 
on trochlear 
groove 
3 groups: defect, 
PRP, and 
PRP+SDSC 
(n=9 each) 
4, 12, 24 weeks 
Pure PRP or 
leukocyte-rich 
PRP (2000 rpm 
for 5 min, 3000 
rpm for 10 min) 
Both PRP and 
PRP+SDSC have neo-
cartilage formation 
based on Safranin O 
staining and collagen 
type II staining; 
PRP+SDSC had 
regular cartilage 
surface integration 
compared to PRP 
group. 
 
(J.-C. C. Lee et 
al., 2013) 
5 mm 
diameter 4 
mm depth 
defect on 
trochlear 
groove 
3 groups: defect, 
PLGA, and 
PLGA+PRP 
(n=8 each) 
Pure PRP or 
leukocyte-rich 
PRP (800 rpm 
for 15 min, 
2000 rpm for 15 
min) 
PLGA+PRP group has 
the best tissue 
morphology, matrix 
staining and total 
score. 
(Y. Sun, Feng, 
Zhang, Chen, & 
Cheng, 2010) 
3 mm 
diameter 5 
mm depth 
defect on 
femoral 
condyles 
2 groups: intra-
articular 
injection of PRP 
or saline (n=4 
each) 
3. 6, 12 weeks 
Leukocyte-rich 
PRP (1200 x g 
for 17 min) 
No significant 
improvement was 
detected because of 
PRP administration. 
(Smyth et al., 
2016) 
5 mm 
diameter 5 
mm depth 
trochlear 
groove 
3 groups: defect, 
PRP, or 
injectable PRF 
(n=4 each) 
4 and 12 weeks 
Pure PRP (900 
x g for 5 min, 
2000 x g for 15 
min); leukocyte-
rich PRF (60 x 
g for 5 min) 
At week 12, no 
significant difference 
was observed between 
macroscopically but 
injectable PRF had the 
highest ICRS score 
microscopically. 
 
(Abd El Raouf 
et al., 2017) 
4 mm 
diameter 3 
mm depth 
trochlear 
groove 
6 groups: defect, 
PRP, PRF, 
gelatin+SDF1, 
PRP+SDF1, or 
PRF+SDF1 (n=6 
each) 
4 weeks 
Pure PRP or 
leukocyte-rich 
PRP (2000 rpm 
for 5 min, 3000 
rpm for 10 min) 
; CaCl2 added 
before use; 
leukocyte-rich 
PRF (3000 rpm 
for 10 min) 
PRF+SDF1 is the best 
based on collagen type 
II staining and 
toluidine blue staining 
among all six groups at 
4 weeks. 
(Bahmanpour, 
Ghasemi, 
Sadeghi-Naini, 
& Kashani, 
2016) 
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Table 3 (continued) 
Trochlear 
groove 
4 groups: control, 
hydrogel, 
hydrogel+cells, 
hydrogel 
+cells+PRP 
4 weeks 
Pure PRP or 
leukocyte-rich 
PRP (1500 rpm 
for 10 min, 
3000 rpm for 
10 min) 
Hydrogel+cells+PRP is the 
best at 4 weeks. 
(H. R. Lee, 
Park, 
Joung, 
Park, & 
Do, 2012) 
Trochlear 
groove 
3 groups: defect, 
PRP gel, photo-
crosslinkable PRP 
gel (n=8 each) 
12 weeks 
 
Pure PRP or 
leukocyte-rich 
PRP (800 rpm 
for 15 min, 
2000 rpm for 
15 min) 
Photo-crosslinkable PRP gel 
has controlled release of 
TGFβ and the best staining 
of collagen type II at 12 
weeks. 
(Xiaolin 
Liu et al., 
2017) 
Note: PLGA: poly(lactic-co-glycolic acid); SDSC: synovial membrane-derived mesenchymal 
stem cells; SDF1: stromal cell-derived factor-1. 
 
4.2.2  Goat Model 
Under IACUC-approved and -exempted protocol #17081143, we also examined the 
application of PRP, more specifically, anti-VEGF neutralized PRP, in a caprine model. The 
demographic information can be found in the Appendix. The two treatment groups were hydrogel 
and cells with or without anti-VEGF neutralized leukocyte-poor PRP. Cells were derived from the 
stromal vascular fraction of infrapatellar fat pad. More specifically, infrapatellar fat pad was 
surgically removed and collected in the operating room. Fat was minced and digested in 0.6 % 
collagenase type I at 37 degrees C for 60 minutes. Stromal vascular fraction was prepared for each 
goat and resuspended in 10% methacrylated gelatin and 1% methacrylated hyaluronan containing 
2 ug/ml TGFβ3. The cell-hydrogel mixture was prepared for cartilage defect implantation. 
The significance of this model is that goat knee is large, active, and anatomically similar 
to human knee. The proportions of cartilage and subchondral bone in goats are closer to humans 
than other animal models. We utilized caprine model to assess the clinical application for articular 
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cartilage implants. Previously, studies have reported the mechanical and/or histological 
performance of implants for cartilage repair and usually included 3-6 animals per group (Jurgens 
et al., 2013; Levingstone et al., 2016; Lind, Larsen, Clausen, Osther, & Everland, 2008; Miot et 
al., 2012; Pei, Fan, Zhang, Zhang, & Yu, 2014; van Bergen et al., 2013; Zhu, Zhang, Man, Ma, & 
Hu, 2011). We also reviewed literature for appropriate experimental design and sample size 
(Fortier, Hackett, & Cole, 2011; Johnson & Frisbie, 2016).A comparison of saline and leukocyte-
rich PRP (Biomet: 3200 rpm 15 min) for osteochondral defect repair was reported; however no 
significant difference was detected between the saline and the PRP group at 24 weeks (n=8 each) 
(van Bergen et al., 2013). 
The novelty of this study is we utilized autologous cells from infrapatellar fat pads that is 
translational to clinics. To the best of our knowledge, no studies have yet reported the application 
of anti-VEGF neutralized leukocyte-poor PRP. In Chapter 3, we identified the potential inhibitory 
effect of VEGF; literatures have indicated the implications of leukocyte in cartilage repair; 
therefore, we expect the anti-VEGF neutralization can improve the potential application of PRP.   
4.2.3  Future Directions 
One of the limitations in this dissertation is that PRP pooled from several donors was used, 
to examine the overall effect of dosage and treatment duration on IFP-ASC chondrogenesis for a 
given PRP preparation. It is noteworthy that Mazzocca et al. reported that platelet and white blood 
cell numbers vary between individuals and repetitive withdraws of the same individual (Mazzocca, 
2012). We may increase the sample size and examine the effect of different donors individually. 
We may also perform ELISA microarray to quantify the growth factor and cytokine concentration 
in each PRP preparation, and correlate the observed chondrogenic potential to the individual 
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growth factor and cytokine profile, in order to identify more chondro-inhibitory and/or -
stimulatory factors and optimize the PRP treatments. 
Another limitation is that the effect of leukocyte- and platelet-rich plasma (L-PRP) and 
pure platelet-rich plasma (P-PRP) was not compared in this dissertation. Several studies have 
reported that L-PRP and P-PRP prepared from the same batch of whole blood have significantly 
different growth factor and cytokine profile and different osteochondral defect repair outcome in 
animal models (Osterman et al., 2015; Sundman, Cole, & Fortier, 2011; Xu et al., 2017). 
As mentioned earlier, PRP can be in liquid form or gel form (known as platelet-rich fibrin 
or PRF), dependent on the preparation protocol and the presence of platelet activator. It has been 
shown that PRP and PRF also have different repair outcomes in animal models (Maruyama et al., 
2017). 
These directions can provide information on the potential application of PRP in 
combination with cell-based therapy for cartilage repair. Our goal is to develop an optimal cell and 
biologic formulation for a potential point-of-care treatment of post-traumatic and focal cartilage 
defects, for the restoration of joint function and improvement of the quality of life.  
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Appendix A  
Table 4. Demography of human whole blood donors 
Whole Blood Donors Gender Age 
Donor 1 F 48 
Donor 2 M 17 
Donor 3 F 55 
Donor 4 F 24 
Donor 5 M 39 
Donor 6 M 26 
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Table 5. Sequences of human RT-PCR primers 
Gene Forward Sequence (5’ to 3’) Reverse Sequence (5’ to 3’) 
18S rRNA GTA ACC CGT TGA ACC CCA TT CCA TCC AAT CGG TAG TAG CG 
SOX9 CTG AGC AGC GAC GTC ATC TC GTT GGG CGG CAG GTA CTG 
COL2 GGA TGG CTG CAC GAA ACA TAC CGG CAA GAA GCA GAC CGG CCC TAT G 
ACAN GCT ACA CTG GCG AGC ACT GTA ACA T GCG CCA GTT CTC AAA TTG CAT GGG 
COL10 GTG TTT TAC GCT GAA CGA TAC CAA ACC TGG TTT CCC TAC AGC TGA TG 
MMP13 ACT GAG AGG CTC CGA GAA ATG GAA CCC CGC ATC TTG GCT T 
COL1 GGG CTC TAA TGA TGT TGA ACT TGT ATG ATT GTC TTT CCC CAT TCA TTT 
RUNX2 CAA CCA CAG AAC CAC AAG TGC G TGT TTG ATG CCA TAG TCC CTC C 
VEGF GCC TTG CCT TGC TGC TCT AC GCA TGG TGA TGT TGG ACT CCT C 
KDR1 AGA CGG ACA GTG GTA TGG TTC CCG AGT CAG GCT GGA GAA TC 
FLT1 TTG ATG ACT ACC AGG GCG ACA G GGA GTA CAG GAC CAC CGA GTT G 
NRP1 GGC TCT CAC AAG ACC TTC TG ACT CCT CTG GCT TCT GGT AG 
NRP2 AAA CGG CAA GGA CTG GGA ATA C TGG TTG TCT CTT CGC TCT TCA C 
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Table 6. Antibodies for flow cytometry and antibody neutralization 
Antibody Company Catalog Number Isotype Application 
CD31 BD Biosciences 558068 Mouse IgG Flow Cytometry 
CD34 BD Biosciences 550761 Mouse IgG Flow Cytometry 
CD44 BD Biosciences 550989 Mouse IgG Flow Cytometry 
CD45 BD Biosciences 560975 Mouse IgG Flow Cytometry 
CD73 BD Biosciences 550257 Mouse IgG Flow Cytometry 
CD90 BD Biosciences 555595 Mouse IgG Flow Cytometry 
CD105 BD Biosciences 560839 Mouse IgG Flow Cytometry 
VEGFR1 R&D Systems FAB321P Mouse IgG Flow Cytometry 
VEGFR2 R&D Systems FAB357P Mouse IgG Flow Cytometry 
VEGFR3 R&D Systems FAB3492P Mouse IgG Flow Cytometry 
TGFβR2 R&D Systems FAB2411P Goat IgG Flow Cytometry 
PDGFRb BD Biosciences 558821 Mouse IgG Flow Cytometry 
VEGF R&D Systems MAB293 Mouse IgG Antibody Neutralization 
IgG R&D Systems MAB004 Mouse IgG Antibody Neutralization 
VEGFR1 Abcam ab32152 Rabbit IgG Antibody Neutralization 
VEGFR2 Abcam ab2349 Rabbit IgG Antibody Neutralization 
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Table 7. Demographic profile of donor rabbits for rabbit cell isolation  
Rabbit Donors Gender Weight (kg) Adipose Tissue (g) Stromal Vascular Fraction 
Rabbit 1 F 4.4 61.0 1.0 x 107 cells 
Rabbit 2 F 3.7 33.9 1.6 x 107 cells 
Rabbit 3 F 3.6 19.7 1.5 x 107 cells 
Rabbit 4 F 3.6 23.7 1.6 x 107 cells 
Rabbit 5 F 4.0 36.8 1.8 x 107 cells 
Rabbit 6 F 3.1 14.9 0.2 x 107 cells 
Under IACUC-approved and -exempted protocol #15063708 and #16025372 
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Table 8. Information of rabbit implantation 
Rabbit # DLAR # Gender Treatment Operation Date Sacrifice Date 
1 R691-17 F Hydrogel 2/26/2018 5/21/2018 
2 R692-17 F Hydrogel + Cells 2/26/2018 5/21/2018 
3 R695-17 F Defect 3/1/2018 5/24/2018 
4 R696-17 F Hydrogel 3/1/2018 5/24/2018 
5 R698-17 F Sham 3/5/2018 5/28/2018 
6 R699-17 F Sham 3/5/2018 5/28/2018 
7 R704-17 M Sham 3/5/2018 5/28/2018 
8 R702-17 F Defect 3/8/2018 5/31/2018 
9 R707-17 M Defect 3/8/2018 5/31/2018 
10 R708-17 M Defect 3/8/2018 5/31/2018 
11 R689-17 F Hydrogel + Cells 3/21/2018 6/13/2018 
12 R690-17 F Hydrogel + Cells 3/21/2018 6/13/2018 
13 R709-17 M Hydrogel + Cells 3/21/2018 6/13/2018 
14 R710-17 M Hydrogel + Cells 3/21/2018 6/13/2018 
15 R700-17 F Hydrogel  3/28/2018 6/20/2018 
16 R701-17 F Hydrogel  3/28/2018 6/20/2018 
17 R711-17 M Sham 3/28/2018 6/20/2018 
18 R712-17 M Hydrogel + Cells + PRP 3/28/2018 6/20/2018 
19 R703-17 F Hydrogel + PRP 4/2/2018 6/25/2018 
20 R713-17 M Hydrogel + PRP 4/2/2018 6/25/2018 
21 R714-17 M Hydrogel + PRP 4/2/2018 6/25/2018 
22 R693-17 F Hydrogel + Cells + PRP 4/9/2018 7/2/2018 
23 R716-17 M Hydrogel + Cells + PRP 4/9/2018 7/2/2018 
24 R717-17 M Hydrogel + Cells + PRP 4/9/2018 7/2/2018 
25 R718-17 M Hydrogel + Cells + PRP 4/9/2018 7/2/2018 
26 R314-18 M Hydrogel + PRP  5/10/2018 8/2/2018 
27 R315-18 M Sham 5/10/2018 8/2/2018 
28 R316-18 M Defect 5/10/2018 8/2/2018 
29 R317-18 F Hydrogel + PRP  5/14/2018 8/6/2018 
30 R318-18 F Hydrogel + Cells + PRP  5/14/2018 8/6/2018 
31 R319-18 F Hydrogel + Cells + PRP 5/14/2018 8/6/2018 
Under IACUC-approved and -exempted protocol #17106357; data updated on May 14, 2018. 
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Table 9. Complete blood count of whole blood and PRP for rabbit surgery 
DLAR #  Platelet x 
103/µL 
WBC x 
103/µL 
Neutrophil Lymphocyte Monocyte Eosinophil Basophil 
R693-17 
WB 152 5.5 25% 65% 7% 1% 2% 
PRP 331 1.5 26% 48% 22% 4% * 
R703-17 
WB 252 6.6 30% 54% 4% 2% 10% 
PRP 389 0.3 * * * * * 
R712-17 
WB * * * * * * * 
PRP 63 0.1 * * * * * 
R713-17 
WB 300 5.4 34% 60% 1% 2% 3% 
PRP 392 0.1 * * * * * 
R714-17 
WB 217 7.4 41% 48% 6% 3% 2% 
PRP 147 0.3 * * * * * 
R717-17 
WB 308 7.2 30% 62% 5% 1% 2% 
PRP 420 1.0 * * * * * 
R718-17 
WB 449 4.8 45% 49% 6% * * 
PRP 942 0.1 * * * * * 
R314-18 
WB 324 6.4 27% 64% 4% 3% 2% 
PRP 563 1.3 * * * * * 
R317-18 
WB 249 5.9 31% 62% 4% 1% 2% 
PRP 238 1.6 * * * * * 
Under IACUC-approved and -exempted protocol #17106357; WB: whole blood; PRP: platelet-
rich plasma; WBC: white blood cell; *: no results; data updated on May 14, 2018. 
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Table 10. Information of goat implantation 
Goat # DLAR # Gender Treatment Surgery Date Sacrifice Date 
1 G2-18 F Hydrogel + Cells 2/22/2018 8/22/2018 
2 G3-18 F Hydrogel + Cells 2/22/2018 8/22/2018 
3 G9-18 F Hydrogel + Cells 3/15/2018 9/15/2018 
4 G10-18 F Hydrogel + Cells 3/15/2018 9/15/2018 
5 G1-18 F Hydrogel + Cells 3/22/2018 9/22/2018 
6 G4-18 F Hydrogel + Cells 3/22/2018 9/22/2018 
7 G5-18 F Hydrogel + Cells + Anti 
VEGF Neutralized PRP 
3/26/2018 9/26/2018 
8 G6-18 F Hydrogel + Cells + Anti 
VEGF Neutralized PRP 
3/26/2018 9/26/2018 
9 G7-18 F Hydrogel + Cells + Anti 
VEGF Neutralized PRP 
3/29/2018 9/29/2018 
10 G8-18 F Hydrogel + Cells + Anti 
VEGF Neutralized PRP 
3/29/2018 9/29/2018 
Under IACUC-approved and -exempted protocol #17081143; data updated on May 14, 2018.  
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